TARGETING PROTEIN KINASE D BY NOVEL SMALL MOLECULE INHIBITORS AND RNA INTERFERENCE IN PROSTATE CANCER by LAVALLE, COURTNEY
 TARGETING PROTEIN KINASE D BY NOVEL SMALL MOLECULE INHIBITORS 
AND RNA INTERFERENCE IN PROSTATE CANCER 
 
 
 
 
 
 
 
by 
 
Courtney Rebecca LaValle 
 
Bachelor of Science, University of California, Irvine 2006 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
 
The School of Medicine in partial fulfillment 
 
of the requirements for the degree of 
 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
University of Pittsburgh 
 
2011 
 
  
ii
 
UNIVERSITY OF PITTSBURGH  
 
The School of Medicine 
 
 
 
 
 
 
 
This dissertation was presented  
 
by 
 
 
Courtney Rebecca LaValle 
 
It was defended on  
 
June 24, 2011 
 
and approved by  
 
Chairman Guillermo G. Romero, Ph.D., Professor, Department of Pharmacology and Chemical 
Biology 
 
John S. Lazo, Ph.D., Professor, Department of Pharmacology and Chemical Biology 
 
Shivendra Singh, Ph.D., Professor, Department of Pharmacology and Chemical Biology 
 
Peter Wipf, Ph.D., Professor, Department of Chemistry 
 
Shi-Yuan Cheng, Ph.D., Associate Professor, Department of Pathology 
 
Dissertation Advisor: Q. Jane Wang, Ph.D., Associate Professor, Department of Pharmacology 
and Chemical Biology 
  
iii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © by Courtney Rebecca LaValle 
2011
  
iv
 
 
 
 
 
TARGETING PROTEIN KINASE D BY NOVEL SMALL MOLECULE INHIBITORS 
AND RNA INTERFERENCE IN PROSTATE CANCER 
 
Courtney Rebecca LaValle, Ph.D. 
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Protein kinase D (PKD) has been implicated in a variety of cellular processes and 
pathological conditions including cancer. However, targeting PKD therapeutically and dissecting 
PKD-mediated cellular responses remains difficult due to lack of a potent and selective inhibitor. 
Here, we report the discovery of a novel class of pan-PKD inhibitors, CID755673 and its 
analogs. Subsequently, we use these inhibitors in conjunction with RNA interference technology 
to show that PKD regulates prostate cancer cell growth and motility. CID755673 was discovered 
in collaboration with our colleagues at the University of Pittsburgh as a compound demonstrating 
nanomolar potency and high selectivity for PKD inhibition. To enhance its selectivity and 
potency for potential in vivo application, several analogs of CID755673 were generated. After 
initial activity screening, 5 analogs having equal or greater in vitro potencies as CID755673 were 
chosen for further analysis. Our data showed that modifications to the aromatic core structure 
significantly increased potency while retaining high specificity for PKD. In prostate cancer cells, 
all compounds inhibited phorbol 12-myristate 13-acetate (PMA)-induced autophosphorylation of 
PKD1, with kb-NB142-70 being most active. Importantly, these inhibitors caused a dramatic 
arrest in cancer cell proliferation. Migration and invasion were also inhibited by this class of 
compounds, with varying potencies that correlated to their cellular activity, suggesting an active 
role for PKD in these processes. To confirm PKD involvement in prostate cancer biology, we 
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used short hairpin RNA (shRNA)- and small interfering RNA (siRNA)-mediated knockdown of 
specific PKD isoforms, demonstrating that knockdown of PKD2 and/or PKD3 significantly 
reduces proliferation, migration, and invasion in metastatic PC3 prostate cancer cells. We also 
found that inhibition of PKD expression or activity decreases secretion of several key tumor-
promoting factors including matrix metalloproteinase (MMP)-9, interleukin (IL)-6, IL-8, and 
growth-regulated oncogene α (GROα). Finally, we demonstrated that inducible knockdown of 
PKD3 in both subcutaneous and orthotopic xenograft models leads to reduced prostate tumor 
growth. Taken together, these data provide much-needed pharmacological tools for the study of 
PKD function, validate PKD as a promising therapeutic target in prostate cancer treatment, and 
broaden our understanding of the molecular mechanisms of PKD function in prostate cancer 
progression. 
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1.0  INTRODUCTION 
 
PKD constitutes a novel family of serine/threonine kinases and diacylglycerol (DAG) receptors 
that signal downstream of G protein-coupled receptors (GPCRs) and tyrosine kinase receptors. 
Now classified as a subfamily of the calcium/calmodulin-dependent kinase (CaMK) superfamily, 
the three PKD isoforms, PKD1/PKCµ (Johannes et al. 1994; Valverde et al. 1994), PKD2 
(Sturany et al. 2001), and PKD3/PKCν (Hayashi et al. 1999), have emerged as key regulators of 
many important cellular processes. Major advances in our understanding of PKD signaling have 
emerged in the following fields:  
1) Basic signaling mechanisms (Rozengurt et al. 2005; Waldron et al. 1999), where PKD 
has been identified as a protein kinase C (PKC) effector (Zugaza et al. 1996).  
2) Protein trafficking (Bankaitis 2002; Cuenda and Nebreda 2009; Ghanekar and Lowe 
2005), where PKD, a Golgi-resident kinase, has been shown to regulate protein transport 
from the Golgi to the plasma membrane (Bossard et al. 2007; Jamora et al. 1999; 
Liljedahl et al. 2001; Martiny-Baron et al. 1993; Yeaman et al. 2004), a significant 
function of PKD that underlies its critical role in multiple secretory processes including 
the secretion of insulin from pancreatic beta cells (Sumara et al. 2009)  and cell motility 
(Prigozhina and Waterman-Storer 2004; Woods et al. 2004).  
3) Immune system function (Matthews et al. 2006), where PKD was found to play an 
important role in mediating antigen-receptor signaling (Marklund et al. 2003; Matthews 
et al. 2006) and in regulating lymphocyte adhesion and motility (Medeiros et al. 2005).  
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4) Oxidative stress responses (Storz 2007; Storz et al. 2003), where PKD was shown to 
be activated by oxidative stress and to promote cell survival through activation of nuclear 
factor-kappaB (NFκB) signaling (Storz et al. 2003; Storz et al. 2005; Waldron and 
Rozengurt 2000).   
5) Angiogenesis (Altschmied and Haendeler 2008; Ha and Jin 2009) and cardiovascular 
biology (Haworth and Avkiran 2001; McKinsey 2007), where PKD can mediate vascular 
endothelial growth factor (VEGF) signaling  (Wong and Jin 2005) and promote 
angiogenesis in part through regulation of class IIa histone deacetylase (HDAC) activity 
(Ha et al. 2008a; Ha et al. 2008b; Wang et al. 2008), which plays a critical role in 
pathological cardiac remodeling in the heart (Fielitz et al. 2008; Vega et al. 2004).  
6) Drug discovery (LaValle et al. 2010b), where emerging PKD inhibitors, beginning 
with our discovery of CID755673 (Sharlow et al. 2008), are proving to be useful in the 
study of PKD function and are showing promise in preclinical models of cancer 
(Harikumar et al. 2010; LaValle et al. 2010a) (reviews and papers from leading research 
groups in these areas are cited).  
These functions of PKD are intimately coupled to its potential role in tumor development. Most 
notably, the regulation of immune system function, protein trafficking, oxidative stress, and 
angiogenesis are known to impact many aspects of tumor biology, which will be discussed in 
more detail in following sections. 
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1.1 STRUCTURE AND REGULATION OF PKD ENZYMES 
 
Though the three-dimensional structure of PKD has not yet been resolved, several studies have 
provided insight into the structural features of the PKD enzymes. All 3 isoforms of PKD share a 
distinct structure that includes a catalytic domain, a pleckstrin homology (PH) domain, and an N-
terminal cysteine-rich DAG/phorbol ester binding domain (the C1 domain) (Hayashi et al. 1999; 
Johannes et al. 1994; Sturany et al. 2001; Valverde et al. 1994). High homology between the 
isoforms exists, particularly in the catalytic domain and C1 domain, though there are differences 
in the N-terminal region and in regions flanked by the C1 and PH domains which may confer 
isoform-specific functions (Wang 2006). The PH domain has a negative regulatory effect on 
PKD catalytic activity, as deletion of this domain leads to constitutive activation of the kinase 
(Iglesias and Rozengurt 1998). 
 The regulatory mechanisms that control PKD activity have been well-documented. 
Studies have shown that PKD is activated through direct phosphorylation of 2 conserved serine 
residues in the activation loop by DAG-responsive PKC isoforms (Waldron et al. 1999; Waldron 
and Rozengurt 2003; Zugaza et al. 1996). Subsequent autophosphorylation then confers full, 
sustained activation (Jacamo et al. 2008; Matthews et al. 1999). This canonical PKC/PKD 
activation pathway can be further “tuned” by other factors and pathways. For example, the Src-
Abl pathway has been shown to prime PKD for activation by PKCδ through tyrosine 
phosphorylation in the PH domain (Storz et al. 2003; Storz et al. 2004). Furthermore, it has also 
been demonstrated that, while initial catalytic activation of PKD requires PKC, sustained 
activation of PKD in response to GPCR agonists is maintained by an autophosphorylation 
mechanism at Ser742 of the activation loop (Jacamo et al. 2008; Sinnett-Smith et al. 2009). As a 
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DAG target, PKD is also subjected to spatial regulation by DAG or phorbol esters. Binding of 
DAG to the C1 domain allows PKD to localize to the plasma membrane and trans Golgi network 
(TGN), mediating site-specific functions (Wang 2006). PKD also shuttles between the cytoplasm 
and the nucleus and can demonstrate transient nuclear accumulation upon activation or through 
specific signals (Rey et al. 2001; Rey et al. 2003; von Blume et al. 2007). PKD can be activated 
in response to a variety of stimuli, including DAG, phorbol esters, growth factors, GPCR 
agonists, and hormones (Guha et al. 2002; Matthews et al. 1997; Rozengurt et al. 1997; Wong 
and Jin 2005; Zugaza et al. 1997). 
 
 
1.2  SIGNALING MECHANISMS OF PKD: RELEVANCE TO TUMOR CELL 
BIOLOGY 
  
Emerging evidence links PKD to a diverse set of signal transduction pathways involved in tumor 
development and cancer progression (Figure 1). Here, we will discuss the potential roles and 
signaling mechanisms of PKD in cancer-associated biological responses. 
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Figure 1. PKD involvement in cancer-related signal transduction pathways. PKD has been implicated in the 
regulation of multiple cancer-promoting pathways. PKC-mediated activation of PKD has been shown to regulate 
such cellular functions as proliferation, apoptosis, the epithelial to mesenchymal transition, angiogenesis, and 
invasion. Dysregulation of these fundamental pathways can lead to the development, progression, and metastasis of 
cancer.  
 
1.2.1  Cell proliferation, survival, and apoptosis 
Uncontrolled cell growth and resistance to apoptosis are among the hallmarks of cancer 
development. Functional studies have described PKD as a potent promoter of cell growth and 
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proliferation in multiple cellular systems, suggesting that PKD may possibly contribute to the 
cancer phenotype. For example, in Swiss 3T3 cells, overexpression of PKD has been shown to 
potentiate DNA synthesis in response to bombesin, vasopressin, and phorbol esters (Zhukova et 
al. 2001), and expression of PKD1 has been shown to correlate with levels of proliferating-cell 
nuclear antigen (PCNA) and proliferation state in mouse keratinocytes (Rennecke et al. 1999). 
Furthermore, treatment with the PKC/PKD inhibitor Gö6976 inhibits 3H-thymidine incorporation 
in keratinocytes (Shapiro et al. 2002), supporting a role for a PKC/PKD axis in the regulation of 
keratinocyte proliferation. A similar role for PKD was also demonstrated in prostate and 
pancreatic cancer (Chen et al. 2008; Trauzold et al. 2003).   
Mechanistically, PKD has been linked to several pathways known to control cell 
proliferation, most notably the extracellular signal-regulated kinase (ERK) signaling pathway. 
Inhibition of PKD expression and activity has been shown to attenuate ERK signaling, while 
overexpression of PKD has been shown to potentiate ERK activity in response to growth factors 
in multiple cell types including endothelial cells, Swiss 3T3 cells, and prostate cancer cells (Chen 
et al. 2008; Sinnett-Smith et al. 2004; Sinnett-Smith et al. 2007; Wong and Jin 2005). It has been 
proposed that PKD modulates the Ras-Raf-MEK-ERK pathway and promotes proliferation, 
possibly through direct phosphorylation of the Ras effector protein Ras and Rab interactor 1 
(RIN1) (Van Lint et al. 2002; Wang et al. 2002). Separate studies have suggested PKD may 
mediate endothelial cell proliferation and growth through regulation of class IIa HDACs (Wang 
et al. 2008). 
PKD is also implicated in the regulation of cell survival and apoptosis. Substantial work 
has shown that PKD promotes survival and inhibits apoptosis through modulation of the NF-κB 
and c-Jun N-terminal kinase (JNK) pathways (Storz 2007; Storz et al. 2005; Zhang et al. 2005). 
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Interestingly, in an opposing role, PKD can promote anoikis, cell death resulting from 
detachment from the extracellular matrix, by modulating the phosphorylation and subsequent 
localization of Bcl-2 inhibitor of transcription 1 (Bit1) (Biliran et al. 2008). Additionally, PKD 
was found to be cleaved by caspase-3 in response to certain genotoxic agents, a process that 
generates catalytically active PKD fragments that may play a role in sensitizing cells to the 
cytotoxic effects of these agents (Endo et al. 2000; Vantus et al. 2004). Furthermore, several 
PKD substrates including sphingosine kinase 2 (SphK2) and heat-shock protein 27 (Hsp27) have 
also been connected to the apoptotic response, but the functional relevance of their regulation by 
PKD in apoptosis remains to be determined (Ding et al. 2007; Doppler et al. 2005; Hassan et al. 
2009). 
 
1.2.2  Cell migration and invasion 
PKD has been implicated in several pathways mediating cell migration, invasion, and motility – 
processes that are critical to cancer progression and metastasis. Consistent with its important role 
as a modulator of protein trafficking, PKD1 regulates fibroblast motility and Rac-1-dependent 
leading edge activity through modulation of anterograde membrane traffic from the TGN to the 
plasma membrane (Prigozhina and Waterman-Storer 2004). Furthermore, PKD directs the 
transport of αvβ3 integrin to focal adhesions, affecting cell migration (Woods et al. 2004). PKD-
mediated phosphorylation of several proteins important to cell migration and invasion, including 
cortactin (De Kimpe et al. 2009), Par-1 (Watkins et al. 2008), and slingshot 1 like (SSH1L) 
(Eiseler et al. 2009b), has also been documented. SSH1L is a phosphatase whose activity causes 
reactivation of the actin-remodeling protein cofilin at the leading edge of migrating cells (Nishita 
et al. 2005). Pioneering work by the Storz group showed that phosphorylation of SSH1L by 
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PKD1 leads to its dissociation from the actin cytoskeleton and subsequent inhibition of cell 
motility through sustained cofilin inactivation (Eiseler et al. 2009b).  
Extensive studies in breast cancer cells have also demonstrated a role for PKD1 in cell 
motility. As early as 1999, Mueller and colleagues described an interaction between PKD1, 
paxillin, and cortactin at sites of invadopodia in MDA-MB-231 breast cancer cells (Bowden et 
al. 1999). Invadopodia are actin-containing protrusions that extend outward into the extracellular 
matrix (ECM) and participate in degradation of the ECM (Stylli et al. 2008). This interaction, 
present in invasive breast cancer cells but not in non-invasive lines, suggests that PKD1 may 
regulate the function or formation of the paxillin/cortactin complex to promote invasion. 
Furthermore, cortactin was recently determined to be a PKD1 substrate (De Kimpe et al. 2009), 
albeit 10 years after these initial studies were first published. However, whether this 
phosphorylation event and the PKD1/cortactin/paxillin association does indeed promote invasion 
is still not known. Additional studies have shown that PKD and its substrates are involved in the 
regulation of MMP expression (Eiseler et al. 2009a; Ha et al. 2008a; Lee et al. 2008). MMPs are 
matrix-degrading enzymes that control cell migration and invasion and have been linked to the 
progression of many types of cancer (Roy et al. 2009). Future studies are needed to fully 
elucidate the role of PKD in these events.   
 
1.2.3  Angiogenesis 
Angiogenesis is the process through which new blood vessels are formed. In tumor development, 
angiogenesis is required to provide growing primary and secondary tumors with oxygen and 
nutrients (Hanahan and Weinberg 2000). A study in 2005 by Wong and Jin showed that PKD 
was activated by VEGF downstream of PKCα and regulated endothelial cell proliferation (Wong 
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and Jin 2005). Further studies showed that VEGF-induced endothelial cell proliferation, 
migration, and in vivo angiogenesis all required PKD activity (Qin et al. 2006). Subsequently, 
researchers from 2 separate groups reported that VEGF-stimulated activation of PKD leads to 
PKD-dependent phosphorylation of HDAC7 and increased migration in endothelial cells (Ha et 
al. 2008a; Wang et al. 2008). This pathway was also shown to promote several additional 
processes required for angiogenesis including proliferation (Wang et al. 2008), tube formation, 
and microvessel sprouting (Ha et al. 2008a). These studies stemmed from the seminal work by 
Vega et al. that first identified class IIa HDACs as direct substrates of PKD (Vega et al. 2004). 
Class IIa HDACs, including HDAC4, -5, -7, and -9, catalyze the deacetylation of lysine residues 
in histone amino-terminal tails and, as part of large, multiprotein transcriptional co-repressor 
complexes, regulate the activity of transcription factors such as myocyte enhancer factor-2 
(MEF2) (Martin et al. 2007). Direct phosphorylation of class IIa HDACs by PKD leads to 
nuclear exclusion of these proteins and subsequent expression of MEF2 target genes, including 
the angiogenesis-promoting MMPs (Ha et al. 2008a; Wang et al. 2008). 
 
1.3  PKD IN PROSTATE CANCER: EXPRESSION, ACTIVITY, AND 
LOCALIZATION 
 
Prostate cancer, the second leading cause of death from cancer among men in the U.S. in 2009 
(Jemal et al. 2009), is characterized by generally slow-growing tumors localized in the prostate 
gland, a walnut-sized structure that wraps around the urethra. Despite recent advances in early 
diagnosis and screening procedures, there are currently no effective therapeutic treatments once 
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tumors have metastasized (Shirai 2008). We still have an incomplete understanding of the 
molecular mechanisms that cause prostate cancer to become invasive.  
 
1.3.1  PKD expression in prostate cancer 
PKD has emerged as a major player in cell proliferation, survival, motility, and angiogenesis 
pathways, and it is therefore no surprise that PKD has recently received considerable attention as 
a potential target in the treatment of cancer. Studies assessing the expression levels of all 3 
isoforms have shown that, indeed, PKD is dysregulated in several cancer types, including breast, 
pancreatic, gastric, and prostate cancers, and that the up- or downregulation of specific PKD 
isoforms may be related to tumor stage and context (Table 1).  
 
Table 1. Dysregulation of PKD isoforms in human tumor samples determined by 
immunohistochemistry analysis 
PKD 
Isoform 
Tumor 
Type Expression* Correlation/Notes 
PKD1 Breast  
– 
Reduced PKD1 in invasive tumorsa 
 Pancreatic + Increased PKD1 and activated PKD1/2 in tumors
b,c
 
 
 Prostate + 
– 
Increased PKD1 in tumor tissuesd 
 
Reduced PKD1 in androgen-independent tumorse 
 
 Basal Cell 
Carcinoma 
+ Elevated and misdistributed PKD1 in the hyperproliferative 
human skin disorders, BCC and psoriasisf 
 
 Gastric 
– 
Decreased PKD1 in tumors, correlated with increased 
PKD1 promoter methylationg 
PKD2 Breast no change - 
 
 Lymphoma no change PKD2 expression pattern in different lymphomas 
correspond to its expression in normal counterpartsh  
PKD3 Breast no change - 
 
 Prostate + Increased PKD3 in tumor tissues
d
 
Increased PKD3 nuclear accumulation, correlated with 
pathological graded 
*Indicates the change in expression compared to normal tissue of the corresponding organ. (+) indicates 
upregulation, while (–) indicates downregulation in tumor tissues. a(Eiseler et al. 2009a); b(Harikumar et al. 2010); 
c(Trauzold et al. 2003); d(Chen et al. 2008); e(Jaggi et al. 2003); f(Ristich et al. 2006); g(Kim et al. 2008); 
h(Kovalevska et al. 2006). 
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Recently, evidence for the role of PKD in the progression of prostate cancer has been 
revealed. Studies have shown that PKD1 and PKD3 expression levels are elevated in human 
prostate carcinoma tissues compared to normal prostate epithelial tissue, and advanced-stage 
tumors were found to have increased PKD3 nuclear accumulation (Chen et al. 2008). In contrast, 
androgen-independent tumors showed reduced PKD1 expression (Jaggi et al. 2003). Common 
prostate cancer cell lines also display differential expression of the PKD isoforms. The LNCaP 
cell line, an androgen-sensitive and less metastatic cell line, expresses PKD1 and PKD2 only, 
while DU145 and PC3 cells, both androgen-insensitive and highly metastatic prostate tumor 
cells, express primarily PKD3, with moderate expression of PKD2 and no detectable PKD1 
(Chen et al. 2008). While epigenetic silencing of PKD1 has been demonstrated in breast and 
gastric cancers (Eiseler et al. 2009a; Kim et al. 2008), studies have not yet investigated the 
mechanisms modulating the selective expression of PKD1 and PKD3 isoforms in specific 
prostate cancer cell lines. It is likely that there is a relationship between the androgen-
independent state and PKD isoform expression, as the above mentioned studies in angroden-
independent prostate cancer tissues and cell lines suggest (Chen et al. 2008; Jaggi et al. 2003). 
Androgen independence appears to be associated with reduced expression of PKD1 in both 
studies. However, whether androgen independence drives the silencing of PKD1 or lack of 
PKD1 contributes to the development of the androgen-independent state remains to be 
determined. Nonetheless, the differential expression and distribution of PKD in these cell lines 
and in tumor samples suggests PKD might be important for the progression of prostate cancer, 
and that specific PKD isoforms may mediate distinct cancer-related functions at different stages 
of prostate cancer progression, in a cell context-dependent manner.  
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1.3.2  Functional role of PKD in prostate cancer 
Functional analysis of PKD has revealed distinct roles for the PKD isoforms in prostate cancer. 
Balaji and colleagues (Mak et al. 2008) demonstrated a tumor suppressor-like function for PKD1 
in prostate cancer. PKD1 was found to negatively regulate androgen receptor (AR) function and 
prostate cancer cell migration and proliferation. Specifically, expression of PKD1 in DU145 cells 
reduced cell proliferation, while co-expression of kinase-dead PKD1 with AR attenuated the AR-
mediated increase in cell-proliferation (Mak et al. 2008). Furthermore, expression of either 
PKD1 or the kinase-dead PKD1 mutant reduced AR-mediated transcription. Additional studies 
have suggested that repression of AR-dependent transcription by PKD1 may be mediated 
through Hsp27 (Hassan et al. 2009). They have also demonstrated that overexpression of PKD1 
may promote cell aggregation, inhibit migration, and reduce cell proliferation through 
phosphorylation of E-cadherin and regulation of β-catenin activity, linking PKD1 to the Wnt 
signaling pathway (Du et al. 2009; Jaggi et al. 2008; Jaggi et al. 2005; Syed et al. 2008). These 
studies are suggestive of a possible role for PKD1 in suppressing the development of the 
androgen-independent state, common to more advanced, aggressive prostate cancer. It is possible 
that the silencing of PKD1 is a necessary step in the progression of metastatic prostate cancer, as 
has been suggested for both breast and gastric cancers (Eiseler et al. 2009a; Kim et al. 2008). 
Further comprehensive studies are needed to determine whether the PKD1 isoform indeed acts as 
a tumor-suppressor in prostate cancer. 
In contrast, separate studies conducted in our laboratory have demonstrated a positive 
role for the PKD3 isoform in prostate cancer cell proliferation and survival (Chen et al. 2008). In 
androgen-independent PC3 cells, where PKD3 has high endogenous expression, reduction of 
PKD3 levels using siRNA caused potent inhibition of cell proliferation. Analysis of a potential 
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mechanism revealed that PKD3 activity stimulated prolonged activation of Akt and ERK1/2. 
This regulation of Akt and ERK1/2 may account for the effects on proliferation, and also may 
affect other steps in prostate cancer progression. Akt, commonly found to be hyperactive in 
prostate cancer due to a phosphatase and tensin homolog (PTEN)-null phenotype, has been 
implicated in angiogenesis and metastasis in addition to its fundamental roles in survival and 
proliferation (Nelson et al. 2007; Sarker et al. 2009). Further evidence presented later in this 
dissertation demonstrates that PKD3 does indeed promote proliferation, migration, and invasion 
in androgen-independent prostate cancer cells (see Chapters 4 and 5). 
  These studies not only highlight the significance of PKD signaling in prostate cancer 
progression, but also strongly suggest isoform-specific functions and contrasting roles for PKD1 
and PKD3 in different prostate cancer cell lines and tissues. These differences can likely be 
explained by variations in cell type and context, with factors such as the androgen-independent 
state and expression profiles of various other tumor suppressors and oncogenes all contributing 
to the function of PKD isoforms. Further studies are needed to conclusively describe these 
potentially distinct and opposing roles for the PKD isoforms in prostate cancer and to determine 
what implications this might have in the development of PKD inhibitors for potential use as 
chemotherapeutic agents in the treatment of prostate cancer. 
 
1.4  CHEMICAL INHIBITORS OF PKD: OLD AND NEW 
 
Novel biotechnologies such as RNAi-mediated knockdown of endogenous proteins now allow 
the study of protein function through direct targeting of specific proteins. The limitations of these 
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approaches, however, are that they irreversibly deplete the entire protein and they are extremely 
difficult to apply in vivo. On the other hand, the development of chemical probes with high 
potency and selectivity provides the opportunity to directly and reversibly target the enzymatic 
activity of PKD in cells and animals. Moreover, one can titrate the level of inhibition. In the past, 
PKD inhibition was achieved by various general kinase inhibitors or through compounds that 
were primarily developed as PKC inhibitors. Recently however, novel chemical inhibitors 
targeting PKD in various disease states including cancer have emerged, with several new 
compounds being developed in the past few years (Table 2). 
In earlier studies, several compounds capable of inhibiting PKD among a range of other 
kinases were reported. The pan-kinase inhibitor staurosporine and staurosporine-related 
compounds such as K252a have been reported to inhibit PKD in the low nanomolar range 
(Figure 2). However, these compounds lack the specificity necessary to interrogate PKD in cells 
(Gschwendt et al. 1996). The indolocarbazole Gö6976 inhibits PKD with an IC50 around 20 nM 
and is commonly used to inhibit PKD in various cellular contexts. However, this inhibitor is 
foremost a classical PKC inhibitor with single digit nanomolar IC50s (Gschwendt et al. 1996; 
Martiny-Baron et al. 1993). Other compounds reported to inhibit PKD include the antioxidant 
and chemopreventive agent resveratrol. Resveratrol inhibits many proteins in addition to PKD, 
and high micromolar concentrations are required for inhibition of PKD (Aggarwal et al. 2004; 
Haworth and Avkiran 2001; Stewart et al. 2000). Despite these limitations, resveratrol has been 
extensively studied as a potential chemotherapeutic and chemopreventive agent, showing potent 
antitumor activity in multiple animal models, and it is possible that a small part of its 
effectiveness is indeed due to inhibition of PKD activity (Aggarwal et al. 2004). In contrast to 
the abovementioned agents, suramin, a hexasulfonated naphthylurea, has been shown to be a 
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novel and effective activator of PKD. Although suramin is a valuable tool for discriminating the 
activities of PKC isozymes, it too is rather unselective, thereby limiting its effectiveness as a 
chemical probe for the study of PKD in a relevant biological environment (Gschwendt et al. 
1998). In recent years, following our discovery of the first potent and selective PKD inhibitor 
(Sharlow et al. 2008), there has been a surge of reports describing novel small molecules 
targeting PKD (Harikumar et al. 2010; LaValle et al. 2010a; Monovich et al. 2009; Raynham et 
al. 2008), which will be discussed in detail in Chapter 3 of this dissertation. 
 
Table 2. In vitro IC50 values for chemical inhibitors of PKD1 
 
Class Structural 
Category 
Compound IC50 PKD1    
(µM) 
Other Biological Activities 
ATP-
competitive 
inhibitors 
Staurosporine-
derived 
Staurosporine 0.04 Broad spectrum kinase inhibitor. Targets 
include PKC, PKA, CaMK II, and p60v-src 
tyrosine protein kinase.a 
 
  Gö6976 0.02 Inhibits PKCα and -β1, TrkA and –B, and 
JAK2 and -3. Inhibits the mitotic spindle.b 
 
  Gö6983 20 Broad spectrum PKC inhibitor. 
Cardioprotective properties.c 
 
  K252a 0.007 Nonselective kinase inhibitor. Inhibits PKC, 
MLCK, and RTKs, among others.d 
 
  GF 109203X 2 Selective inhibitor of PKCα and -β1. Anti-
inflammatory effects in vivo.e 
 
 Stilbene Resveratrol 200 Antioxidant, antitumor, and anti-inflammatory. 
Inhibits a range of enzymes, including PKCs 
and cytochrome P450.f 
 
 Bipyridyl BPKDi 0.001 Attenuates cardiac hypertrophy.g 
 
 Flavonoid Quercetin 4 Multiple biological functions, including 
antitumor and pro-apoptotic agent. Inhibits 
PKCs, PI3K, mitochondrial ATPase, and 
phosphodiesterases, among others.h 
 
 Aglycone Phloretin 50 Inhibits PKCs and L-type Ca2+ channels. 
PGF2a receptor agonist.i 
 
Non-ATP-
competitive 
Benzoxolo-
azepinone 
CID755673 0.182 Inhibits prostate cancer cell proliferation and 
motility, has mitogen-stimulating effects..j 
 
a (Ruegg and Burgess 1989; Tamaoki et al. 1986; Yanagihara et al. 1991); b (Behrens et al. 1999; Grandage et al. 
2006; Martiny-Baron et al. 1993; Rennecke et al. 1996; Stolz et al. 2009); c (Gschwendt et al. 1996; Peterman et al. 
2004); d (Morotti et al. 2002; Ruegg and Burgess 1989); e (Jacobson et al. 1995; Toullec et al. 1991); f (Aggarwal et 
al. 2004; Chun et al. 1999; Haworth and Avkiran 2001); g (Monovich et al. 2009); h (Graziani et al. 1983; 
Gschwendt et al. 1996; Picq et al. 1989; Wei et al. 1994); i (Gschwendt et al. 1996; Kitanaka et al. 1993; 
Prevarskaya et al. 1994); j (Sharlow et al. 2008; Torres-Marquez et al. 2010). 
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A significant obstacle in the development of novel PKD inhibitors with high potency and 
selectivity is the current lack of information regarding the three-dimensional (3D) structure of 
PKD, preventing the use of structure-based drug design as a strategy for future development of 
PKD chemical probes. Structure-based drug design is a powerful approach that has been widely 
used to develop targeted therapies against many cancer targets, including BCR-ABL, 
phosphoinositide 3-kinase (PI3K), Hsp90, p53, and epidermal growth factor receptor (EGFR) 
(van Montfort and Workman 2009). The availability of structural information on PKD would 
greatly accelerate the optimization of current lead compounds and would potentially facilitate the 
targeting of specific interactions between PKD and its substrates or binding partners. 
Furthermore, it might provide significant insight into structural differences between the PKD 
isoforms that could be exploited in the development of isoform-selective inhibitors. 
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Figure 2. Chemicals commonly used to inhibit PKD. Staurosporine, Gö6976, K252a, and resveratrol inhibit PKD, 
but are rather unselective. They are active site inhibitors, competing with ATP. Suramin, a PKD activator, is a useful 
tool for differentiating PKC isoforms, but its application is similarly hampered by a lack of selectivity.  
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1.5  PKD AS A CHEMOTHERAPEUTIC TARGET 
 
Extensive evidence indicates that PKD expression is deregulated in multiple cancer types and 
plays an active role in a variety of cancer-associated biological processes including proliferation, 
survival, apoptosis, migration, invasion, and angiogenesis, making PKD an attractive target for 
drug discovery. However, the prominent lack of animal models to support the potential role of 
PKD in cancer remains a significant gap in knowledge in this field. To date, there have been no 
reports in the literature describing whether specific targeting of PKD in animal models alters the 
initiation and progression of any type of cancer. Recently, tumor xenograft studies have shown 
that treatment with the novel PKD inhibitor CRT0066101 reduced tumor growth in both 
subcutaneous PANC-1 tumors and in orthotopically implanted PANC-1 tumors (Harikumar et al. 
2010). However, since this compound has not yet been completely characterized with regards to 
specificity toward PKD, it cannot be concluded that this effect was mediated through PKD. 
Indeed, further studies describing the specific targeting of PKD in animal models are needed to 
validate PKD as a potentiat chemotherapeutic target. 
 A wide range of studies have characterized PKD as being a promoter of cell proliferation 
and survival. However, it is important to note that PKD may have cell-specific and isoform-
specific functions, especially with regards to motility, and data suggests that the PKD1 isoform 
may even act as a tumor suppressor in certain types of cancer. In prostate cancer, where reports 
have indicated potential opposing roles for PKD1 and PKD3 (Chen et al. 2008; Du et al. 2009; 
Jaggi et al. 2003; Sharlow et al. 2008), isoform selectivity may prove to be a limiting factor in 
treatment efficacy. 
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 It is important to note that while global PKD1 knockout results in embryonic lethality in 
mice (Fielitz et al. 2008), gene-trapping studies have revealed that mice deficient in PKD2 
develop normally and are indistinguishable from their wild-type littermates (Matthews et al. 
2010), and deletion of PKD3 results only in only mild abnormalities in bone development 
(Lexicon Genetics 2005). Conditional global knockout of any PKD isoform in adult mice has not 
yet been described; thus it is difficult to predict potential side effects of chemotherapeutic agents 
targeting PKD in adult cancer patients.    
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2.0  MATERIALS AND METHODS 
 
 
 
 
2.1  CHEMICALS AND REAGENTS 
 
DMSO was purchased from Sigma. CID755673 and its analogs, kb-NB142-70, kb-NB165-09, 
kb-NB165-31, kb-NB165-92, and kb-NB184-02, were synthesized in Dr. Peter Wipf’s laboratory 
at the Department of Chemistry, University of Pittsburgh, according to standard organic 
synthesis procedures (Amir 2006; Connor et al. 1992; Connor 1989; Grimm et al. 2003; Khatana 
1996; Lyubchanskaya 2002). 
 
 
2.2 SYNTHESIS OF CID755673 
 
CID755673 and its byproduct CID797718 were synthesized by Dr. Peter Wipf’s laboratory at the 
University of Pittsburgh, according to experimental protocols published in multiple reports 
(Bravo-Altamirano et al. 2011; Sharlow et al. 2008). 
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2.3 IN VITRO RADIOMETRIC PKD OR CAMK KINASE ASSAY 
 
In vitro radiometric kinase assays were conducted to determine the inhibitory activity of the 
novel compounds toward PKD and additional kinases. For these assays, 1 µCi [γ-32P] ATP 
(PerkinElmer Life Sciences), 70 µM ATP, 50 ng purified recombinant human PKD1 (Biomol 
International, Plymouth Meeting, PA), PKD2 (SignalChem, Richmond, BC, Canada), or 
CAMKIIα (Enzo Life Sciences), or 75 ng PKD3 (Enzo Life Sciences), and 2.5 µg syntide-2 
(Sigma) was incubated in 50 µL kinase buffer containing 50 mM Tris-HCl, pH 7.5, 4 mM 
MgCl2, and 10 mM β-mercaptoethanol. For the CAMK assay, 0.5 mM CaCl2 and 30 ng/µL 
calmodulin were pre-incubated for 10 min on ice, and then added to each reaction mixture. The 
reaction was incubated at 30°C for 10 min, and 25 µL of the reaction mixture was then spotted 
onto Whatman P81 filter paper (Whatman Inc., Clifton, NJ). The filter papers were washed 3 
times in 0.5% phosphoric acid, air-dried, and counted using a Beckman LS6500 multipurpose 
scintillation counter (Beckman). 
 
 
 
2.4.  IN VITRO RADIOMETRIC PKC KINASE ASSAY 
 
In vitro kinase assays were performed to measure activity of several PKC isoforms. The kinase 
assays were carried out by coincubating 1 µCi of [γ-32P] ATP (PerkinElmer), 20 µM ATP, 100 
ng of purified rat PKCδ protein (a kind gift from Dr. Peter M. Blumberg, NCI, National 
Institutes of Health) or 50 ng of recombinant human PKCα (Cell Signaling Technology and 
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CalBiochem), PKCβI (Cell Signaling Technology), or PKCδ (Enzo Life Sciences) with 5 µg of 
myelin basic protein 4-14, 0.25 mg/mL bovine serum albumin, 0.1 mg/mL 
phosphatidylcholine/phosphatidylserine (80/20%) (1 µM), and 1 µM phorbol dibutyrate in 50 µL 
of kinase buffer containing 50 mM Tris-HCl, pH 7.5, 4 mM MgCl2, and 10 mM β-
mercaptoethanol. The reaction was incubated at 30°C for 10 min, and 25 µL of the reaction 
mixture was spotted onto Whatman P81 filter paper. The filter papers were then washed 3 times 
in 0.5% phosphoric acid, air-dried, and counted using a Beckman LS6500 multipurpose 
scintillation counter. 
 
 
2.5 CELL LINES, CELL CULTURE, AND DEVELOPMENT OF STABLE CELL 
LINES 
 
DU145, LNCaP, and CFPAC cells were maintained in RPMI 1640, PC3 cells were grown in 
Ham’s F12 medium, and PANC1 cells were maintained in DMEM. All of the above cell lines 
were purchasedfrom American Type Culture Collection (ATCC), and were supplemented with 
10% fetal bovine serum (FBS), 1000 U/L penicillin, and 1 mg/mL streptomycin and were 
incubated at 5% CO2 and 37°C. LNCaP cells were additionally supplemented with glucose, 
HEPES, and sodium pyruvate. For development of the tetracycline (tet)-inducible PKD3 shRNA 
stable cell lines, PKD3 shRNA or a scrambled shRNA control were cloned into the 
pENTR/H1/TO vector according to the manufacturer’s instructions (Invitrogen). PC3-TR cells 
(expressing the tet-repressor, a generous gift from Dr. Peter Blumberg) were then transfected 
with the plasmid containing either PKD3 shRNA or the scrambled shRNA control using 
  
39
Lipofectamine 2000 reagent (Invitrogen). Six hours after transfection, the transfection medium 
was replaced with antibiotic-free growth medium. The following day, the cells were replated into 
selection medium containing 1 µg/mL blasticidin and 10 µg/mL Zeocin (Invitrogen). Selection 
medium was refreshed every 3 days for approximately 2 weeks, after which time clones were 
picked and tested for tet-inducible PKD3 knockdown. To induce expression of the shRNA, tet 
was added to the growth medium at a concentration of 1 µg/mL and refreshed every 2 days for 5 
days. Cells were then collected, and PKD3 expression was analyzed by Western blotting and 
quantitative real-time RT-PCR (RT-qPCR). 
 
 
2.6 TRANSIENT KNOCKDOWN OF PKD3 BY SIRNA 
 
Transient silencing of PKD3 was achieved using multiple siRNAs targeting different regions of 
PKD3. A total of 5 siRNA sequences were used: 2 custom designed siRNAs (siPKD3-1: GCT 
GCT TCT CCG TGT TCA AGT CCT A; and siPKD3-2: GCA GAG TGA AAG TTC CAC 
ACA CAT T) and 3 commercially available PKD3 siRNAs (siPKD3-5: CAC GAT ATG TCA 
GTA CTG CAA; siPKD3-6: CGG GAG AGT GTT ACC ATT GAA; and siPKD3-10: CAG 
ACT TGG CTT GAC CTT AGA; purchased from Qiagen). Transient transfection of PC3 or 
DU145 cells was achieved using DharmaFECT reagent according to the manufacturer’s 
instructions (Invitrogen), typically with 40-60 nM final siRNA concentration, and cells were 
used for subsequent experiments 48 h following transfection.  
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2.7 WESTERN BLOTTING ANALYSIS 
 
Western blot analysis was carried out to analyze expression of various proteins. Cells were 
collected in lysis buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 
10% glycerol, 1% Triton X-100, 5 mM EDTA, 20 µM Leupeptin, 1 mM phenylmethylsulfonyl 
fluoride (PMSF), 1 mM NaVO3, and 10 mM NaF, and incubated on ice for 30 min with 
occasional vortexing. Protein concentration was determined using the BCA Protein 
Concentration Assay kit (Pierce). Equal amounts of protein were subjected to SDS-PAGE and 
subsequent electrotransfer to nitrocellulose membranes. Membranes were pre-blocked in 5% 
nonfat milk in Tris-buffered saline with 0.01% Tween-20 (TBS-T) and then incubated with 
primary antibodies in either 5% nonfat milk or 5% BSA overnight at 4°C. Primary antibodies 
against PKD3 (1:1000 dilution; Cell Signaling Technology), PKD2 (1:1000 dilution, Abcam), p-
S916-PKD1 (1:500 dilution, Millipore), p-S742-PKCµ/PKD (1:1000 dilution, Biosource), 
GAPDH (1:3000 dilution), or tubulin (1:3000 dilution, Santa Cruz Biotechnology) were used. 
Membranes were washed in TBS-T and then incubated for 1 h at room temperature with 
secondary anti-rabbit or anti-mouse antibodies conjugated to horseradish peroxidase (HRP, Bio-
Rad). Detection of specific protein bands was facilitated by the enhanced chemiluminescence 
(ECL) Western blotting detection system (Amersham Biosciences).
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2.8  MTT ASSAY 
 
PC3 cells were seeded into 96-well plates (3000 cells/well) and allowed to attach overnight. 
Cells were then incubated in media containing 0.3-100 µM inhibitors for 72 h. 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide methyl thiazolyl tetrazolium (MTT) 
solution was prepared at 2 mg/mL concentration in PBS, sterilized by filtering through a 0.2 µm 
filter, and wrapped in foil to protect from light. Fifty microliters of MTT solution was added to 
each well and incubated for 4 h at 37oC. Then, media was removed and 200 µL DMSO was 
added to each well. The plate was mixed for 5 min and the optical density was determined at 570 
nm on a Victor 3 Multilabel plate reader (Perkin Elmer). 
 
 
2.9 CELL PROLIFERATION ASSAY 
 
Proliferation of PC3, DU145, LNCaP, PANC1, or CFPAC cells in the presence of various 
concentrations of PKD inhibitors (or DMSO as a vehicle control), or of PC3-TR cells or stable 
clones (shScr, shPKD3-1 C7, shPKD3-1 C26, shPKD3-1 C2-1, or shPKD3-1 C2-3) in the 
presence or absence of tet, was measured by counting the number of viable cells upon trypan 
blue staining for 6 consecutive days. For the PC3-TR and stable cell lines, cells were pretreated 
with or without tet (1 µg/mL) for 5 days, and then replated at 5000 cells/well density in 24-well 
plates. Growth media containing inhibitors or tet for all cells was refreshed every 2 days.   
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2.10  CELL CYCLE ANALYSIS 
 
Cell cycle analysis was performed to determine cell cycle distribution under various conditions, 
and was conducted as previously reported (LaValle et al. 2010a; Sharlow et al. 2008). PC3 cells 
were treated with indicated compounds at various concentrations for 2-6 days, and then fixed in 
70% ice-cold ethanol overnight and labeled with propidium iodide. The labeled cells were 
analyzed using a FACScan Benchtop Cytometer (BD Biosciences). 
 
 
2.11 WOUND HEALING ASSAY 
 
Wound-induced migration was measured using the “wound healing” or “scratch” assay (LaValle 
et al. 2010a; Sharlow et al. 2008). In this assay, PC3, DU145, CFPAC, or PANC1 cells, or the 
stable clones shScr, shPKD3-1 C7, or shPKD3-1 C26 were grown to confluence in 6-well plates. 
Stable clones were pretreated with tet for 5 days prior to the experiment to induce PKD3 
knockdown. Migration was initiated by scraping the monolayer with a pipette tip, creating a 
“wound.” The indicated concentration of compound or the inducing agent, tet, was added to the 
media, and the wound was imaged immediately under an inverted phase-contrast microscope 
with 10X objective. After the indicated times, cells were fixed in methanol and stained with 1% 
crystal violet, and a final image was taken. The wound gap was measured, and the percentage 
wound healing was calculated. The average percent wound healing was determined based on 
either at least 9 measurements of the length of the wound gap or at least 3 measurements of the 
wound area. For the wound healing assay using conditioned medium, shScr or shPKD3-1 C7 
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cells were treated with tet for 5 days and then replated to normalize the cell number into serum-
free medium. After 48 h, the serum-free conditioned medium was collected, centrifuged briefly 
to remove floating cells, and an equal volume from each cell line was applied to confluent PC3 
cells. The wound healing assay was then performed as above. 
 
 
2.12 MATRIGEL INVASION ASSAY 
 
DU145, PC3, or CFPAC cells (5.0-8.0 x 104 cells/mL) in RPMI containing 0.1% fetal bovine 
serum (FBS) were seeded into the top chamber of BioCoat control inserts (pore size 8 µm) or 
BioCoat Matrigel invasion inserts with Matrigel-coated filters (BD Pharmingen). To stimulate 
invasion, media in the lower chamber of the insert contained 20% FBS. Inhibitors or tet were 
added at the indicated concentrations to both the upper and lower chambers, and cells were 
incubated for 22 h at 37°C with 5% CO2. After incubation, noninvasive cells were removed 
using a cotton swab, and invasive cells were first fixed in 100% methanol and then stained with 
1% crystal violet. After staining, cells were counted under a microscope (200x magnification). 
The percentage invasion was determined by cell counts in at least 5 fields of the number of cells 
that invaded the Matrigel matrix relative to the number of cells that migrated through the control 
insert. For experiments on the stable tet-inducible cell lines shScr or shPKD3-1 C7, cells were 
first pretreated with or without tetracycline for 5 days to induce PKD3 knockdown and then 
subjected to the Matrigel invasion assay as described above. For transient knockdown of PKD2 
and/or PKD3, PC3 cells were transfected with specific siRNAs using DharmaFECT reagent 
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(Dharmacon, Thermo Fisher Scientific). Forty-eight hours following transfection, cells were 
subjected to the invasion assay. 
 
 
2.13 QUANTITATIVE REAL-TIME RT-PCR 
 
Total RNA was isolated from shScr, shPKD3-1 C2-1, and shPKD3-1 C2-3 PC3-TR cells using 
RNeasy Mini Kit (Qiagen, Valencia, CA). Reverse-transcription was performed using the iScript 
cDNA synthesis kit (Bio-Rad, Hercules, CA), typically on 1 µg total RNA, according to the 
manufacturer’s instructions. RT-qPCR was then performed on a CFX96 Real-time Detection 
System with the C1000 Thermal Cycler (Bio-Rad), using SsoFast EvaGreen master mix (Bio-
Rad) in a 10 µL total reaction volume. Primer pairs, used at 500 nM final concentration, were 
designed based on guidelines provided by Bio-Rad, and their specificity was confirmed by 
BLAST search. Sequences of the primer pairs used were as follows: GAPDH, GCA AAT TCC 
ATG GCA CCG T (forward) and TCG CCC CAC TTG ATT TTG G (reverse); PKD3, CAT 
GTC CAC CAG GAA CCA AG (forward) and GAC GGG TGT AAG AGT GAA CAG C 
(reverse); MMP-9, GAC GCA GAC ATC GTC ATC CAG TTT (forward) and GCC GCG CCA 
TCT GCG TTT (reverse); MMP-14, CGC TAC GCC ATC CAG GGT CTC AAA (forward) and 
CGG TCA TCA TCG GGC AGC ACA AAA (reverse); IL-6, ACA TCC TCG ACG GCA TCT 
CAG (forward) and AAT CTG AGG TGC CCA TGC TAC (reverse); IL-8, TTT GCC AAG 
GAG TGC TAA AGA (forward) and GCA TCT GGC AAC CCT ACA ACA (reverse); 
GROα/CXCL-1, CCA AAG TGT GAA CGT GAA GTC C (forward) and GGA TGC AGG ATT 
GAG GCA AG (reverse). The PCR protocol included 1 cycle at 95°C for 30 s, then 40 cycles of 
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a 95°C for 5 s step followed by 5 s at either 62°C or 65°C, depending on the optimal annealing 
temperature for each primer set, which had been determined experimentally. Melt curves were 
conducted to assure specificity of the primer sets as well as absence of primer-dimers. PCR 
efficiencies for the primer sets were determined by creating a standard curve using dilutions of 
the cDNA, as suggested by the manufacturer’s protocol. PCR efficiencies were within the 
acceptable range (90-115%) for all primer sets. Relative transcript abundance was calculated by 
BioRad CFX96 Manager software using the ∆∆Ct method with GAPDH as the reference gene. 
 
 
2.14 ZYMOGRAPHY 
 
Levels of latent and active MMP-2 and MMP-9 in conditioned medium were determined using 
gelatin zymography (Kleiner and Stetler-Stevenson 1994; Troeberg and Nagase 2004). Briefly, 
serum-free conditioned medium was collected for 48 h from PC3 cells undergoing various 
treatment conditions. If necessary, the conditioned medium was concentrated up to 10-fold using 
Amicon Ultra-0.5 mL Centrifugal Filters (Millipore, Billerica, MA). Non-reducing sample buffer 
(5X) containing 400 mM Tris-HCl, 5% SDS, 20% glycerol, and bromophenol blue was added to 
the conditioned medium, and the samples were run at a constant 180 V on a 10% polyacrylamide 
gel co-polymerized with 0.1% gelatin (Sigma-Aldrich, St. Louis, MO) until the dye front reached 
the bottom of the gel. Purified recombinant MMP-9 and MMP-2 (R&D Systems, Minneapolis, 
MN) were run alongside the samples to serve as standards. Gels were then washed once with 
2.5% Triton X-100 and incubated 1 h at room temperature in fresh 2.5% Triton X-100 to remove 
SDS from the gel. To facilitate activation of MMPs within the gel, gels were then incubated in 
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buffer containing 50 mM Tris-HCl, pH 7.5, 200 mM NaCl, 5 mM CaCl2, and 0.02% Brij-35 for 
18 h at 37°C with gentle rotation. After overnight incubation, gels were stained with 0.5% 
Coomassie Brilliant Blue R250 for 3 h and destained 3 h using destain solution (30% methanol, 
10% acetic acid) with 3 changes or until clear bands were easily visible on the dark background. 
 
 
2.15 MEMBRANE-BASED CYTOKINE ANTIBODY ARRAY 
 
Analysis of cytokine secretion into conditioned medium was performed using the Human 
Cytokine Array I (RayBiotech, Norcross, GA), according to the manufacturer’s instructions. 
Briefly, serum-free conditioned medium from untreated and tet-treated shScr and shPKD3-1 C7 
cells was collected as described above. Antibody array membranes were placed in an 8-chamber 
plate and pre-blocked at room temperature for 1 h using 2 mL of blocking buffer. Conditioned 
medium samples were then applied and incubated overnight at 4°C. Membranes were washed 3 
times for 5 min each wash in wash buffer I, followed by 1 x 5 min wash in wash buffer II. The 
membranes were then incubated for 2 h at room temperature with biotin-conjugated antibody 
mix. Washing was repeated as before, and the arrays were then incubated with HRP-conjugated 
strepavidin for 1 h at room temperature. The membranes were washed again as before, and then 
spots were visualized using the ECL Western blotting detection system (Amersham 
Biosciences). 
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2.16 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
 
Quantitative measurement of cytokines secreted into the conditioned medium was detected using 
ELISA kits (RayBiotech, Norcross, GA). Serum-free conditioned medium was collected from 
various cells for 48 h as described above and ELISA analysis was carried out following the 
manufacturer’s protocol. Standard curves were determined using known amounts of recombinant 
IL-6, IL-8, or GROα protein, and the level of each cytokine in the collected conditioned medium 
was extrapolated based on the standard curve. Sensitivities of the assays were approximately 3.0 
pg/mL, 1.0 pg/mL, and 50 pg/mL for IL-6, IL-8, and GROα/CXCL-1, respectively. For the 
ELISA using tumor lysates, frozen tumors were sliced into small pieces and tumor cells were 
homogenized for 1 min in lysis buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1.5 
mM MgCl2, 10% glycerol, 5 mM EDTA, 20 µM Leupeptin, 1 mM PMSF, 1 mM NaVO3, and 10 
mM NaF. After homogenization, 1% Triton X-100 was added, and cells were incubated on ice 
with vortexing for 1 h. Lysates were then centrifuged at top speed for 15 min to remove debris, 
and protein concentration was determined using the BCA Protein Concentration Assay kit 
(Pierce). Equal amounts of protein were subjected to ELISA according to the manufacturer’s 
instructions. 
 
 
2.17 SUBCUTANEOUS XENOGRAFT MOUSE MODEL 
 
Tumor cells (shScr, shPKD3-1 C7, or shPKD3-1 C26 clones) were resuspended in growth 
medium and mixed with BD Matrigel Basement Membrane Matrix (BD Biosciences) at a final 
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cell concentration of 4x106 cells per 0.1 mL. Cells were injected subcutaneously into the right 
flank of 6- to 8-week-old male athymic nude mice (Charles River Laboratories, Wilmington, 
MA). Five days after inoculation, palpable tumors had established in 42/44 mice (95.5%). Of the 
2 mice in which tumors did not take, 1 had been inoculated with shScr cells, and 1 had been 
inoculated with shPKD3-1 C7 cells. Both of these mice were monitored for the entirety of the 
study, and tumors failed to establish over the 25-day period. Thus, these mice were excluded 
from analysis. Half of the mice in each group were then treated with 1 mg/mL doxycycline 
(dox), a tetracycline analog, via drinking water (this resulted in 4 groups: shScr No Dox, shScr + 
Dox, shPKD3-1 C7 No Dox, shPKD3-1 C7 + Dox; n = 10-11 mice per group). No other 
additives (i.e., sucrose) were necessary and dox-treated mice drank at similar rates to untreated 
mice. Additionally, no dox-associated weight loss was observed, as has been reported by some 
groups (Cawthorne et al. 2007). Dox-containing water was changed every 2 days. Tumor volume 
was measured with a caliper 3 times per week and was calculated as V (mm3) = (L x W2) / 2, 
where L = the largest diameter and W = the shortest diameter perpendicular to L. Twenty-five 
days after inoculation, mice were euthanized by CO2 inhalation, and tumors were excised for 
analysis. Mice were housed in pathogen-free conditions, and all animal studies were conducted 
in accordance with an IACUC-approved protocol at the University of Pittsburgh.
 
 
 
2.18 ORTHOTOPIC XENOGRAFT MOUSE MODEL 
 
Training in this orthotopic prostate xenograft model was completed in the laboratory of Dr. Julie 
Eiseman. In this experiment, tumor cells were injected directly into the prostates of male nude 
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mice in order to measure growth and metastasis and mimic a more physiological state in the 
microenvironment of the prostate. Tumor cells (shScr or shPKD3-1 C7 clones) were resuspended 
in growth medium and mixed with BD Matrigel Basement Membrane Matrix to achieve a final 
concentration of 5 x 105 cells per 10 µL. Male athymic nude mice age 8-weeks (Charles River 
Laboratories, Wilmington, MA) were given the analgesic buprenorphine at 0.1 mg/kg 
subcutaneously 12 h prior to surgery and again just before the procedure. Mice were anesthetized 
using 60 mg/kg pentobarbital were considered ready for the surgical procedure when they did not 
respond to toe-pinch. All procedures were completed under sterile conditions, and tools were 
resterilized between mice using an Inotech Steri 350 glass bead sterilizer (Inotech). For the 
surgery, a 1-cm incision was made through the skin and peritoneum across the lower abdomen, 
exposing the abdominal cavity. The bladder was exposed, and the prostate, located at the base of 
the bladder, was identified. Ten microliters of the cell-Matrigel solution was then injected 
directly into the left dorsolateral lobe (n = 3-4 mice per group). The bladder was replaced into the 
abdominal cavity, and the incision was closed using coated vicryl sutures (Ethicon) in the 
peritoneum and 7.5 mm Michel wound clips (Roboz Surgical Instrument Co., Gaithersburg, MD) 
in the skin. Post-operatively, mice were monitored 2-3 times per day for signs of pain and were 
treated with buprenorphine subcutaneously every 12 h for 3 days to minimize pain. After this 
period, mice were monitored for signs of pain or other complications daily and weighed 3 times 
per week. Two weeks following surgery, most mice had tumors which could be carefully 
palpated through the abdomen. At this point, dox was added to the drinking water at 1 mg/mL 
concentration. Dox-containing water was changed every 2 days. Thirty-one days after 
inoculation, when extreme weight loss was observed in some mice, all mice were euthanized by 
CO2 inhalation, and necropsies were performed. The primary prostate tumor was removed and 
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weighed, and any observable metastases were also excised. All animal studies were conducted in 
accordance with an IACUC-approved protocol at the University of Pittsburgh.
 
 
 
2.19  STATISTICAL ANALYSIS 
 
All statistical analyses were completed using Graph Pad Prism V software. The student’s t-test 
was used to determine the statistical significance of differences seen in Western blotting, RT-
qPCR, cell proliferation, wound healing, invasion, and ELISA assays. For the animal studies, the 
Mann-Whitney-Wilcoxon test was used. A p-value of < 0.05 was considered statistically 
significant. 
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3.0  DEVELOPMENT AND CHARACTERIZATION OF NOVEL SMALL 
MOLECULE INHIBITORS OF PROTEIN KINASE D 
 
 
3.1  INTRODUCTION 
 
The PKD family is a novel family of serine/threonine kinases and diacylglycerol (DAG) 
receptors. Three isoforms of PKD have been identified: PKD1 (formerly PKCµ), PKD2, and 
PKD3 (PKCν) (Hayashi et al. 1999; Johannes et al. 1994; Sturany et al. 2001; Valverde et al. 
1994). All isoforms contain a catalytic domain, a cysteine-rich DAG-binding domain (C1), and a 
pleckstrin homology (PH) domain that negatively regulates PKD activity (Iglesias and Rozengurt 
1998). DAG regulates both the localization of PKD through binding to its C1 domain (Valverde 
et al. 1994) and the activity of PKD through regulating PKC-dependent phosphorylation of PKD 
on serines 738 and 742 (Ser738/742) in the activation loop (Waldron et al. 2001; Waldron and 
Rozengurt 2003). Rapid, early activation of PKD by PKC then leads to autophosphorylation of 
PKD on serine 916 (Ser916) and subsequent full activation of PKD (Matthews et al. 1999). 
Interestingly, evidence has suggested that while Ser742 transphosphorylation by PKC is required 
for early activation of PKD, Ser742 is also a site of autophosphorylation, and that 
autophosphorylation at this site is required for maintaining prolonged PKD activation (Jacamo et 
al. 2008). 
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 Since its discovery, PKD has been implicated in various cellular functions significant to 
tumor development including proliferation, survival, apoptosis, angiogenesis, and motility. For 
example, PKD activation in response to vascular endothelial-derived growth factor (VEGF) or 
bombesin leads to activation of extracellular signal-regulated kinase (ERK) 1/2, regulating cell 
proliferation in several cell types (Sinnett-Smith et al. 2007; Wong and Jin 2005). PKD can also 
be activated by oxidative stress, which modulates cell survival through the NF-κB and JNK 
signaling pathways (Biswas et al. 2010; Hausser et al. 2005; Storz 2007; Zhang et al. 2005). 
Furthermore, PKD has been implicated in the regulation of the epithelial to mesenchymal 
transition in prostate cancer cells by modulation of β-catenin, and angiogenesis in vascular 
endothelial cells through modulating phosphorylation and nucleocytoplasmic shuttling of class 
IIa HDACs (Bertos et al. 2001; Du et al. 2009). Disruption of these fundamental pathways could 
potentially lead to the development, progression, and metastasis of cancer. For example, in 
recent studies, PKD expression has been shown to be dysregulated in human prostate cancer 
tissues (Chen et al. 2008; Jaggi et al. 2003), implicating PKD in the progression of prostate 
cancer. To support this, we previously reported that knockdown of PKD3, a member of the PKD 
family, using siRNA caused a dramatic arrest in cell proliferation in PC3 cells (Chen et al. 2008). 
Additional studies have shown that PKD expression is also dysregulated in pancreatic, breast, 
and gastric cancers, among others (LaValle et al. 2010b).  
This involvement of PKD in a myriad of cancers, as well as other pathological conditions 
such as cardiac hypertrophy (Monovich et al. 2009; Vega et al. 2004), makes it an attractive 
target for drug discovery. Furthermore, besides the potential to target PKD therapeutically, the 
development of novel small molecule PKD inhibitors would facilitate the study of PKD biology 
in vitro and in cellular models. As discussed in Chapter 1, the study of PKD function and 
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signaling has greatly depended on the use of general kinase inhibitors and PKC inhibitors. 
Clearly, these compounds lack the necessary specificity to truly define PKD function. Moreover, 
since PKD signals downstream of PKC in many of its roles, it is especially important that 
compounds used to interrogate PKD function in cellular models show very little activity toward 
the PKC isoenzymes. 
In this study, we report the discovery of CID755673 and its analogs as novel PKD 
inhibitors. With the aim of developing novel pharmacological tools to study PKD function and 
target PKD therapeutically, we conducted assays to evaluate the potency, mechanisms, and 
biological activities of this novel class of compounds. The analogs were synthesized in the 
laboratory of Dr. Peter Wipf, with modifications to both their core structures and side chains 
according to a thorough SAR analysis (Bravo-Altamirano et al. 2011; George et al. 2011). We 
show that CID755673 has potent PKD inhibitory effects, and several of the novel analogs exhibit 
increased potency toward PKD inhibition both in vitro and in cells. Additionally, CID755673 
and its analogs cause potent growth arrest, moderate cell death, and inhibition of migration and 
invasion in prostate and pancreatic cancer cells, supporting their potential for in vivo 
applications.  
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3.2  RESULTS 
 
3.2.1 The discovery of CID755673, a novel PKD inhibitor 
 
3.2.1.1 CID755673 inhibits PKD in vitro 
In 2008, our collaborators, Drs. John S. Lazo and Elizabeth R. Sharlow, at the University of 
Pittsburgh Drug Discovery Institute developed an immobilized metal affinity for 
phosphochemical (IMAP)-based fluorescence polarization (FP) high throughput screening (HTS) 
assay and identified the compound CID755673 as a potential hit (Figure 3). In this HTS, the 
PMLSC 196,173 member library was interrogated, and CID755673 emerged as a small molecule 
that produced >50% inhibition of PKD1 activity when screened at 10 µM (Pubchem AID 797) 
(Sharlow et al. 2008). Further analysis of this compound by our collaborators revealed an IC50 of 
0.50 ± 0.03 µM for PKD1 in the IMAP-FP PKD assay, while the compound appeared to lack 
activity toward PLK1, CAK, or protein kinase B (AKT/PKB) (Sharlow et al. 2008). Upon 
interrogation of the PubMed database, they found that CID755673 appeared to show exquisite 
specificity for PKD and was not biologically active in more than 200 other assays (Sharlow et al. 
2008).    
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Figure 3. Chemical structure of the selective PKD inhibitor CID755673. This compound is a pan-PKD inhibitor 
with an IC50 for PKD1 inhibition of 182 nM. 
 
 
Following the identification of CID755673 as a potential hit in this IMAP-based HTS 
performed by our colleagues, we tested the compound in a traditional in vitro radiometric kinase 
activity assay to confirm its inhibition of PKD1 and determine its IC50 for PKD1 inhibition. In 
this assay, recombinant PKD1 was incubated with the substrate peptide syntide-2, ATP, and 
CID755673 (ranging from 1 to 10,000 nM). We found that CID755673 was a potent inhibitor of 
PKD1, having an IC50 for PKD1 inhibition of 182 ± 27 nM (n = 5) in this assay (Figure 4A). 
Given the high homology of the PKD isoforms, we also investigated whether CID755673 may 
inhibit PKD2 and PKD3 in similar in vitro radiometric kinase activity assays. Indeed, we found 
that CID755673 inhibited both PKD2 and PKD3 with IC50s comparable to that for PKD1 
inhibition (Figure 4B-C). No selectivity for any isoform by CID755673 was noted.
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Figure 4. In vitro inhibitory activity of CID755673 toward the PKD isoforms. The kinase activities of PKD1 
(A), PKD2 (B), and PKD3 (C) were assayed in the presence of 10 different concentrations of CID755673 by a 
radiometric kinase activity assay. The IC50 values were calculated, and the graphs show the mean ± S.E. IC50s 
determined from at least 3 independent experiments with triplicate determinations at each concentration. The data 
were plotted as a function of CID755673 concentration, and a representative graph is shown for each kinase. 
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3.2.1.2 Inhibition of PKD1 by CID755673 in LNCaP cells 
The initial rapid activation of PKD1 in response to GPCR agonists and phorbol esters is 
mediated through phosphorylation of the activation loop serines (Ser738 and Ser742) by PKC and 
subsequent autophosphorylation at Ser916 (Iglesias and Rozengurt 1998; Matthews et al. 1999; 
Waldron and Rozengurt 2003). Maintenance of PKD1 activation in response to prolonged 
stimulation requires autophosphorylation at Ser742 (Jacamo et al. 2008). The phosphorylation 
state of these critical serine residues has been shown to correlate well with PKD activity 
(Matthews et al. 1999). In LNCaP cells, where PKD1 is the predominant isoform (Chen et al. 
2008), PKD activity can be stimulated by addition of phorbol 12-myristate 13-acetate (PMA). 
Thus, we determined whether pretreatment with CID755673 could inhibit PMA-induced 
phosphorylation of PKD1 at the autophosphorylation site Ser916 and the trans- and 
autophosphorylation site Ser742 in LNCaP cells. Cells were pretreated with various 
concentrations of CID755673 for 45 min, PKD activity was stimulated by PMA for 20 min, and 
cell lysates were analyzed by Western blotting for presence of p-Ser916-PKD1 and p-Ser742-
PKD1. We found that CID755673 was indeed able to inhibit activation of PKD1 in cells in a 
concentration-dependent manner, with a near full blockage of autophosphorylation at Ser916 
when cells were exposed to 50 µM CID755673 (Figure 5). Though the compound inhibited both 
Ser742 and Ser916 phosphorylation, inhibition at Ser916 was more dramatic. In contrast, the 
inactive analog CID797718 did not inhibit cellular PKD1 activity (Figure 5).  
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Figure 5. Inhibition of endogenous PKD1 activity by CID755673 in cells. LNCaP cells were pretreated with 
different doses of CID755673 or CID797718 for 45 min, followed by PMA stimulation at 100 nM for 20 min. Cell 
lysates were subjected to immunoblotting for p-Ser742-PKD1 and p-Ser916-PKD1. PKD1 was blotted as loading 
control. Note that the low p-Ser916-PKD1 signal in lane 2 (PMA alone) was likely caused by uneven loading. The 
experiment was repeated 5 times, and a representative blot is shown. 
 
 
3.2.1.3 Analysis of the mechanism of action of CID755673 
Having confirmed that CID755673 inhibited PKD in vitro and in cells, we next wanted to gain 
insight into the mechanism of action of this compound. First, we examined the effects of 
increasing concentrations of ATP on inhibition of PKD1 activity by CID755673. As shown in 
Figure 6A, the compound effectively inhibited PKD1 even in the presence of up to 640 µM 
ATP. Varying the ATP concentration did not alter the IC50 of CID755673 for PKD1 inhibition. 
An Eadie-Hofstee plot was generated by plotting the reaction velocity (v) versus the v/[ATP] 
ratio for each inhibitor concentration and fitting the points to linear regression lines (Figure 6B). 
In this plot, we observed that lines generated for each inhibitor concentration were parallel, 
indicating that addition of increasing concentrations of ATP did not alter the Km (the slope of the 
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line) of the reaction. In contrast, the Vmax (the intercept with the y-axis) decreased as inhibitor 
concentration increased. These results indicate that CID75573 is non-competitive with respect to 
ATP. 
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Figure 6. CID755673 is a non-ATP competitive inhibitor of PKD1. A, ATP competition analysis. PKD1 kinase 
activity was measured as a function of increasing concentrations of CID755673 in the presence of varying 
concentrations of ATP. B, Eadie-Hofstee plot analysis. The reaction velocity (v) was plotted as a function of the 
velocity versus ATP concentration ratio (v/[ATP]) for each concentration of CID755673. The points were fitted by 
linear regression analysis. 
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 Next, we tested whether increasing the concentration of the peptide substrate syntide-2 
could alter the inhibitory activity of CID755673. Similar to our assays with ATP competition, we 
found that the IC50 did not change significantly when the concentration of syntide-2 was varied 
from 6.6 µM to 106.1 µM (Figure 7A). Analysis using the Lineweaver-Burke plot, in which the 
y-axis is plotted as 1/v and the x-axis is 1/[substrate], demonstrated non-competitive, mixed 
inhibition with respect to substrate (Figure 7B). In mixed inhibition, the inhibitor generally 
binds to an allosteric site separate from the substrate binding site, and while inhibitor binding 
may affect substrate binding (and vice versa), the inhibitory effects cannot be overcome by 
increased concentrations of substrate. In this type of inhibition, inhibitor binding may alter either 
the Km or Vmax, or both (Cook and Cleland 2007). To further confirm this result, we repeated this 
analysis using an HDAC5 peptide substrate. We found that this peptide, a more physiologically 
relevant substrate as HDAC5 is phosphorylated by PKD in cells, generated similar results to that 
of syntide-2 when plotted in the Lineweaver-Burke plot (Figure 7C). Taken together, our results 
indicate that CID755673 is non-competitive with respsect to ATP, and appears to demonstrate 
non-competitive, mixed inhibition with respect to substrate, as determined using 2 different 
substrate peptides.  
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Figure 7. CID755673 shows non-competitive, mixed inhibition with respect to substrate. A, determination of 
IC50s with varying concentrations of syntide-2. PKD1 kinase activity was measured as a function of increasing 
concentrations of CID755673 in the presence of varying concentrations of substrate. B-C, Lineweaver-Burke plot 
analysis for syntide-2 (B) or HDAC-5 peptide (C) competition assays. The reciprocal of the reaction velocity (1/v) 
was plotted as a function of the reciprocal of the substrate concentration for each concentration of CID755673. The 
points were fitted by linear regression analysis. 
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3.2.1.4 CID755673 does not inhibit PKC or CAMKIIα 
The study of PKD function has been greatly hampered due to lack of a specific inhibitor. 
Compounds previously used to inhibit PKD were more general kinase inhibitors or PKC 
inhibitors. Since PKD is directly phosphorylated by PKC and functions downstream of PKC 
signaling, dissection of the biological function of PKD would be greatly aided by selective PKD 
inhibitors. Therefore, we tested the ability of CID755673 to inhibit several isoforms of PKC or 
the highly homologous CAMKIIα. Even at high concentrations, CID755673 did not show 
significant inhibition of PKCα, PKCβI, or PKCδ in radiometric PKC kinase activity assays 
(Figure 8A-C). As a positive control, the PKC inhibitor GF109203X potently reduced PKC 
activity for all isoforms tested. Similarly, CID755673 failed to inhibit CAMKIIα, reaching only 
30% maximal inhibition at 100 µM concentration (Figure 8D). Taken together, these results 
suggest that CID755673 is a relatively selective PKD inhibitor and does not inhibit several 
related kinases. 
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Figure 8. CID755673 does not inhibit several related kinases. A, CID755673 did not inhibit PKCδ. Inhibitory 
activity of CID755673 for PKCδ was measured using a radiometric kinase activity assay. Inhibition of PKCδ by 
GF109203X was assayed as a control. Data shows a representative graph from 3 separate experiments. B-C, 
CID755673 also did not inhibit PKCα (B) or PKCβI (C) when tested at 100 nM, 1 µM, or 100 µM concentration. As 
a control, the PKC inhibitor GF109203X potently inhibited PKCα and PKCβI activity. Data are shown as the mean 
± S.E.M. of at least 2 independent experiments. ns, not statistically significant; *, p < 0.05; ***, p < 0.001. D, 
inhibition of CAMKIIα was measured by the radiometric CAMK kinase assay. The experiment was repeated twice, 
and a representative curve is shown.  
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3.2.1.5 CID755673 reduces tumor cell proliferation and causes cell cycle arrest 
PKD is a known regulator of cell proliferation, growth, and survival (Wang 2006) and is known 
to be dysregulated in several types of cancer. Therefore, we evaluated the effects of CID755673 
on the proliferation of prostate cancer cells. Cells were plated in 24-well plates, and cell numbers 
in the presence or absence of inhibitor were determined by counting the number of live cells for 
6 consecutive days. CID755673 treatment caused a significant reduction in cell proliferation for 
PC3, DU145, and LNCaP cells over the course of the experiment (Figure 9A-C). In contrast, the 
weaker analog CID797718 showed reduced effects on PC3 cell proliferation when tested at 25 
µM (Figure 9D). Additionally, more dramatic growth-inhibitory effects of CID755673 were 
observed in PC3 cells as compared with LNCaP cells, accompanying significant morphological 
changes from small polygonal or spindle-like shapes to large, flat, and round shapes (Figure 10).  
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Figure 9. CID755673 inhibits prostate cancer cell proliferation. LNCaP (A), PC3 (B), or DU145 (C) cells were 
plated in triplicates in 24-well plates. Cells were allowed to attach overnight. A cell count at day 1 was made, and 
then either vehicle (DMSO) or CID755673 at the indicated concentrations was added. Cells were counted daily for a 
total of 6 days. Fresh media and inhibitor were added every 2 days. The means of triplicate determinations were 
plotted over time. The experiment was repeated at least twice, and results from a representative experiment are 
shown. D, the effect of the weaker analog CID797718 on PC3 cell proliferation. Results from 1 of 2 independent 
experiments are shown. *, p < 0.05; **, p < 0.01; ***, p < 0.001.  
 
DMSO 25 µM  CID755673
PC3
10 µM  CID755673
 
Figure 10. Morphological changes caused by CID755673 in PC3 cells. Phase-contrast images of PC3 cells after 6 
days of CID755673 treatment are shown. 
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In order to provide more insight into the anti-proliferative effects of this compound, we 
analyzed the cell cycle distribution in PC3 cells treated with 10 µM or 25 µM CID755673. Cells 
were treated for 6 days with CID755673, and then subjected to FACS analysis as described in 
the “Materials and Methods.” As shown in Figure 11, treatment with CID755673 caused 
significant arrest in the G2/M phase of the cell cycle. Taken together, these data indicate that 
CID755673 has significant effects on the proliferation of cancer cells. 
 
DMSO
G0G1: 38.5%
G2M: 18.2%
S: 43.4%
10 µM CID755673
G0G1: 31.4%
G2M: 27.0%
S: 41.6%
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G0G1: 30.2%
G2M: 42.0%
S: 27.8%
G0/G1
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Figure 11. CID755673-induced G2/M phase cell cycle arrest. PC3 cells were incubated with vehicle (DMSO) or 
varying concentrations of CID755673 for 6 days. Media with fresh inhibitors was replenished daily. Cell cycle 
distribution was evaluated by flow cytometry after propidium iodide labeling of fixed cells. One of at least 2 
independent experiments is shown.  
 
 
3.2.1.6 CID755673 inhibits tumor cell migration and invasion  
Among its many functions, PKD has been implicated in modulating cell adhesion and motility 
(Bowden et al. 1999; Jaggi et al. 2005; Prigozhina and Waterman-Storer 2004). Therefore, we 
investigated the effects of CID755673 on migration and invasion in prostate and pancreatic 
cancer cells. To study cell migration, we used a wound healing or “scratch” assay. In this assay, 
cells were plated in 6-well plates and allowed to grow to confluence. Then, a “wound” was made 
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in the confluent monolayer using a 10 µL pipette tip. Cells were treated with various 
concentrations of CID755673, and wound-induced migration was measured by comparing the 
wound gap at time 0 versus the wound gap at various times up to 24 h. Interestingly, CID755673 
was found to inhibit cell migration in PC3, DU145, and PANC1 cells when tested at various 
concentrations (Figure 12A-D). Phase contrast images of the wound in DU145 cells after 24 h 
treatment are shown in Figure 12B. In DU145 cells, wound closure was inhibited up to a 
maximum of 50% closure by 25 µM CID755673 while the less potent analog CID797718 did not 
significantly inhibit wound closure (Figure 12E). 
 To determine the effects of CID755673 on prostate cancer cell invasion, we conducted a 
Matrigel invasion assay in DU145 cells. Cells were seeded into Matrigel invasion or control 
chambers in the absence or presence of 25 µM CID755673, using 20% FBS as the 
chemoattractant. As shown in Figure 13, treatment with CID755673 caused a 3-fold reduction in 
invasion (invasion index = 0.32) while CID797718 had no effect. Taken together, these results 
indicate that the novel PKD inhibitor CID755673 suppresses prostate and pancreatic cancer cell 
motility. 
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Figure 12. Effects of CID755673 on tumor cell migration. A, DU145 cells were grown to confluence in 6-well 
plates. The monolayer was wounded and imaged immediately (0 h). Growth media containing vehicle (DMSO) or 
varying concentrations of CID755673 was added. Wound closure was recorded every 6 h up to 24 h. The width of 
the wound is shown as the average of at least 9 determinations per time point. Percent wound healing was calculated 
at each time point as described under “Materials and Methods.” The experiment was repeated 3 times and data are 
the mean ± S.E.M. of the 3 independent experiments. B, Representative images are shown. C-D, the wound healing 
assay in PC3 cells (C) or PANC1 (D) cells was also performed at a single time point (24 h). The experiment was 
repeated 3 times and data are the mean ± S.E.M. of the 3 independent experiments. E, the weaker analog 
CID797718 did not inhibit wound closure. The experiment was repeated twice and a representative graph is shown. 
ns, not statistically significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001.  
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Figure 13. Effects of CID755673 on tumor cell invasion. A, tumor cell invasion was evaluated by a Matrigel 
invasion assay. A fixed number of DU145 cells (1.0 × 105 cells/mL) were seeded into the upper control or invasion 
chamber. After 22 h, non-invading cells were removed, and cells that invaded through the Matrigel were fixed, 
stained, and photographed under a microscope at 200x magnification. B, percent invasion is expressed as the 
number of cells that invaded through the Matrigel matrix relative to the number of cells that migrated through the 
control insert. Cell number was determined by counting total cell number in 10 random fields. The experiment was 
repeated twice, and a representative experiment is shown. C, the weaker analogue CID797718 did not significantly 
inhibit tumor cell invasion. DU145 cell invasion was measured using Matrigel invasion chambers after incubating 
with DMSO or 25 µM CID797718 for 22 h. ns, not statistically significant; **, p < 0.01.  
  
70
3.2.2 Development and characterization of novel analogs of CID755673 
 
3.2.2.1 Design of CID755673 analogs  
CID755673 and CID797718, a structural analog of CID755673, were synthesized by the PMLSC 
Chemistry Core. CID797718 is a byproduct of CID755673 synthesis, and has 10-fold less 
inhibitory activity toward PKD than the parental compound (Sharlow et al. 2008).  
The design of the CID755673 analogs was based on initial structure-activity relationship 
(SAR) analysis (Bravo-Altamirano et al. 2011; George et al. 2011). We dissected the parent 
compound CID755673 into 4 major structural zones in order to elucidate a fundamental SAR 
(Figure 14). In zone I, we modified the phenolic substituent as well as the α-position on the 
aromatic ring. In zone II, we substituted the oxygen ring atom with sulfur and nitrogen. In zone 
III, we altered the ring size by adding or removing methylene groups, as well as substituting the 
benzylic position. In zone IV, we pursued functional group interconversions as well as 
replacement of the amide with heterocyclic groups. Synthesized analogs were tested for PKD1 
inhibition in vitro to determine whether the structural modifications affected inhibitory activity. 
Most of the zone I derivatives were considerably less active than CID755673 in the PKD screen. 
In particular, carbon substituents ortho to the phenol and O-benzylations were detrimental. In 
contrast, ortho-halogenation and O-methylation were well tolerated. Nitrogen replacements in 
zone II were associated with loss of activity, whereas sulfur substitution was not only tolerated 
well but often led to a substantial increase in activity. Among the zone III substitutions, a 
thioether insertion exo to the five-membered heterocycle and an additional methylene group 
(leading to an eight-membered fused ring) were well tolerated. Finally, all zone IV substitutions 
were unsatisfactory, and we decided to retain the amide function of CID755673 in this position. 
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All compounds synthesized and tested, as well as their in vitro inhibitory activity toward PKD1 
and their chemical structures, are listed in Appendix A. 
kb-NB142-70
 
Figure 14. SAR of CID755673 and its analogs. Diagram describing the major structural zones dissected for SAR 
analysis.  
 
 After initial screening and SAR analysis on approximately 50 analogs summarized above, 
5 novel compounds with equal or greater potency for PKD were selected for further testing 
(Figure 15). 
C12H11NO3
M.W. 217.2
O
 
Figure 15. Chemical structures of CID755673 and its analogs. Chemical structures of the parental compound 
CID755673, previously identified and confirmed as a pan-PKD inhibitor, and of 5 analogs of CID755673. 
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3.2.2.2 In vitro activities of CID755673 analogs  
The in vitro inhibitory activities of the novel compounds toward PKD were determined using 
radiometric PKD kinase activity assays. Recombinant human PKD1, -2, or -3 was incubated with 
the substrate, syntide-2, in the presence of 10 different concentrations of each compound. IC50 
values were determined for each compound by plotting percent PKD activity versus compound 
concentration for each point. We found that while the compounds inhibited all 3 PKD isoforms, 
their potency and selectivity varied (Figure 16 and Table 3). The most potent compound was 
found to be kb-NB142-70, which inhibited PKD1 with an IC50 of 28.3 ± 2.3 nM (n = 3), showing 
a 7-fold greater potency than the parental compound (Table 3). This compound was also a robust 
inhibitor of PKD2 and -3, demonstrating respective IC50s of 58.7 ± 4.2 nM (n = 3) and 53.2 ± 3.5 
nM (n = 3). Notably, kb-NB142-70 and kb-NB184-02 exhibited about 2-fold greater selectivity 
toward PKD1. In contrast, the compound kb-NB165-92 was more selective toward PKD3, 
showing approximately 2-fold greater potency toward PKD3 (IC50 = 58.8 ±7.3 nM, n = 3) than 
PKD1 or -2 (IC50 = 111.2 ± 6.0 and 100.7 ±10.9, n = 3, respectively), which is unique among the 
compounds tested. Other compounds, namely kb-NB165-09 and kb-NB165-31, showed similar 
inhibition of all 3 isoforms. Overall, our results demonstrated that core structural modification of 
CID755673 substantially enhanced its potency, but had less effect on isoform selectivity. 
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Figure 16. Inhibition of PKD activity by CID755673 analogs in vitro. A-E, inhibition of recombinant human 
PKD1 in vitro. PKD kinase activity was assayed by a radiometric kinase assay in the presence of increasing 
concentrations of the CID755673 analogs. A 10-point concentration curve was generated for each compound for 
IC50 determination. Each IC50 was determined as the mean ± S.E.M. of 3 independent experiments with triplicate 
determinations at each concentration in each experiment. Representative graphs are shown. 
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Table 3. In vitro inhibitory activity of CID755673 and its analogs for PKD.  IC50 were determined for 
CID755673 and its analogs against PKD1, -2, and -3 using radiometric kinase activity assays. Each IC50 
was calculated as the mean ± S.E.M. of at least 3 independent experiments with triplicate determinations 
at each concentration in each experiment as described in “Materials and Methods.” 
IC50 (nM) 
Compound PKD1 PKD2 PKD3 
CID755673 182 ± 27 (n = 5) 280 ± 1.8 (n = 3) 227 ± 24 (n = 3) 
kb-NB142-70 28.3 ± 2.3 (n = 3) 58.7 ± 4.2 (n = 3) 53.2 ± 3.5 (n = 3) 
kb-NB165-09 82.5 ± 4.6 (n = 4) 141.6 ± 7.4 (n = 3) 98.5 ± 15.3 (n = 3) 
kb-NB165-31 114.1 ± 23.9 (n = 3) 162.9 ± 20.5 (n = 3) 91.1 ± 17.2 (n = 3) 
kb-NB165-92 111.2 ± 6 (n = 3) 100.7 ± 10.9 (n = 3) 58.8 ± 7.3 (n = 3) 
kb-NB184-02 192.8 ± 27.4 (n = 3) 463.2 ± 38.2 (n = 4) 324.7 ± 39.0 (n = 3) 
*n, number of independent experiments 
 
 
3.2.2.3 CID755673 analogs inhibit PMA-induced endogenous PKD1 activation in prostate 
cancer cells  
To determine whether the compounds were active in cells, we tested their ability to inhibit 
activation of PKD1 by PMA in LNCaP prostate cancer cells. We measured both p-Ser916 and p-
Ser742 levels by Western blot analysis to track PKD1 activity. As is shown in Figure 17 (lane 2), 
addition of PMA alone induced phosphorylation of both Ser916 and Ser742 of PKD1. When 
LNCaP cells were pretreated with the novel CID755673 analogs before PMA treatment, 
concentration-dependent inhibition of phosphorylation at both Ser916 and Ser742 of PKD1 was 
observed (Figure 17, lanes 3-7). This effect appeared to be most dramatic for the compound kb-
NB142-70, with a calculated cellular IC50 for inhibition of Ser916 phosphorylation of 2.2 ± 0.6 
µM (n = 3) (Table 4). The compounds kb-NB165-09 and kb-NB165-92 showed similar cellular 
activity, with IC50s of 3.1 ± 0.5 (n = 3) and 2.6 ± 0.7 µM (n = 3) respectively. Consistent with 
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our in vitro data, kb-NB184-02 was again the least potent compound, demonstrating a cellular 
IC50 of 18.6 ± 2.0 µM (n = 3). GAPDH was used as a loading control instead of PKD1 because 
the PKD1 antibody showed a slight inconsistency in detecting phosphorylated and non-
phosphorylated forms of PKD1 (Figure 17 and data not shown). Taken together, these results 
indicated that the analogs were capable of inhibiting PKD1 in intact cells. 
 
 
PMA (100 nM)        - +        +        +        +        +        +           - +         +        +       +         +      +           - +        +        +         +         +       +    
kb-NB142-70 kb-NB165-09 kb-NB165-31
kb-NB184-02kb-NB165-92
p-Ser916-PKD1 
p-Ser742-PKD1 
GAPDH 
p-Ser916-PKD1 
p-Ser742-PKD1 
GAPDH 
Compound (µM)        - veh.   0.5      1         5      10      50           - veh.     0.5       1       5       10      50      - veh.   0.5       1         5        10     50
 
 
Figure 17. Inhibition of PMA-induced endogenous PKD1 activation in LNCaP cells. LNCaP cells were 
pretreated with indicated concentrations of the 5 analogs for 45 min, then stimulated with 100 nM PMA for 20 min. 
Cell lysates were immunoblotted for p-Ser916-PKD1 and p-Ser742-PKD1. GAPDH was blotted as a loading control. 
The experiment was repeated at least 3 times and representative blots are shown. 
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Table 4. Cellular inhibition of PKD1 autophosphorylation at Ser916 by CID755673 analogs. Cellular 
IC50 was determined by densitometry analysis of Western blotting data for PKD1 autophosphorylation at 
Ser916 in LNCaP cells. Each IC50 was calculated as the mean ± S.E.M. of at least 2 independent 
experiments.  
Compound Cellular IC50 (µM) 
kb-NB142-70 2.2 ± 0.6 (n = 3) 
kb-NB165-09 3.1 ± 0.5 (n = 3) 
kb-NB165-31 8.6 ± 2.0 (n = 3) 
kb-NB165-92 2.6 ± 0.7 (n = 2) 
kb-NB184-02 18.6 ± 2.0 (n = 3) 
*n, number of independent experiments 
 
 
3.2.2.4 Specificity of CID755673 and its analogs to PKD  
We previously reported that CID755673 showed selectivity toward PKD and did not inhibit 
several other kinases tested, including PLK1, CAK, protein kinase B (AKT/PKB), PKCα, -βI, -δ, 
or CAMKIIα. To determine whether the novel analogs retained this specificity, we tested the 
compounds against their ability to inhibit PKCα, -βI, -δ, and CAMKIIα in in vitro radiometric 
kinase activity assays. All analogs were poor inhibitors of PKCα and PKCβI, with only slight 
(<50%) inhibitory activity at 10 µM concentration (Figure 18A-B). This was also true for PKCδ 
and CAMKIIα with the exception of kb-NB165-31, which did show nearly 50% inhibitory 
activity toward PKCδ and about 70% inhibition of CAMKIIα activity at 10 µM concentration 
(Figure 18C-D). As a positive control, the potent PKC inhibitor GF109203X showed strong 
inhibition of all 3 of these isoforms (Figure 18A-C). 
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Figure 18. Selectivity of the CID755673 analogs. Inhibition of PKCα (A), PKCβI (B), PKCδ (C), or CAMKIIα 
(D) by each of the 5 analogs was determined at 100 nM, 1 µM, and 10 µM concentrations. In the PKC assays, the 
potent PKC inhibitor GF109203X was used as a control. Data are the mean ± S.E.M. of 3 independent experiments. 
ns, not statistically significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001.   
 
To further investigate the specificity of this series of compounds, a kinase profiling 
experiment was conducted on CID755673, testing 48 additional kinases (Table 5). CID755673 
showed “significant” inhibition (≥ 50%) of 6 out of a total 48 kinases – glycogen synthase 
kinase-3β (GSK3β), casein kinase 1δ (CK1δ), mitogen-activated protein kinase-activated protein 
kinase (MK) 5, MK2, ERK1, and cyclin-dependent kinase 2 (CDK2). As a control, PKD2 
activity was reduced by 95% when treated with 10 µM CID755673. A separate, smaller scale 
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analysis of the kinase inhibition profile of all 5 of the CID755673 analogs was also conducted, 
and similar patterns of inhibition as the parental compound were observed, indicating that the 
analogs of CID75573 act on similar targets (data not shown). 
 
Table 5. Kinase profiling report for CID755673. Forty-eight kinases were interrogated using a single-
dose in vitro kinase assay at 10 µM CID755673. -20 to +20% inhibition, baseline levels; >20 to 49% 
inhibition, compound only marginally actively inhibits the kinase; >50% inhibition, compound is actively 
inhibiting the kinase. The assay was performed by Caliper Life Sciences (Hanover, MD). 
  CID755673, 10 µM   CID755673, 10 µM 
 Kinase Average % Inhibition  Kinase Average % Inhibition 
 ABL 8  KDR 8 
 AKT1 3 
 MAPKAPK2 95 
 AKT2 4  MARK1 12 
 AMPK 35  MET 18 
 AurA 7  MSK1 7 
 BTK -3  p38a 2 
 CAMK4 17  p70S6K 44 
 CDK2 71  PAK2 3 
 CHK1 7  PDGFRα 5 
 CHK2 4  PDK1 22 
 CK1δ 82  PIM2 6 
 c-Raf 2  PKA 6 
 EGFR 11  PKCη 40 
 ErbB4 1  PKCγ 30 
 Erk1 50  PKCθ 32 
 Erk2 31  PKCζ -4 
 FGFR1 16 
 PKD2 95 
 FLT3 14  PKG1α 13 
 GSK3β 86  PKG1β 11 
 IGF1R -2 
 MK5/PRAK 75 
 Ikkb 49  RSK1 29 
 IBSR 3  SGK1 9 
 IRAK4 0  SRC 7 
 JNK2 36  SYK -8 
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3.2.2.5 Effects of the CID755673 analogs on tumor cell death, proliferation, and cell cycle 
distribution 
Given the effects of PKD3 knockdown by siRNA or CID755673 in the inhibition of prostate 
cancer cell proliferation (Chen et al. 2008; Sharlow et al. 2008) and the implications that PKD 
regulates cell survival and proliferation (Guha et al. 2002; Wong and Jin 2005), we wanted to 
test whether the new compounds were cytotoxic and whether they also inhibited prostate cancer 
cell proliferation. Therefore, we determined the cytotoxic effects of the compounds on PC3 cells 
by MTT assay. As shown in Figure 19, the parental compound induced very little cell death, 
having an EC50 of 319.8 µM in this context. In contrast, the analogs showed considerable 
increases in cytotoxicity. The new lead compound kb-NB142-70 was again the most potent, 
causing considerable cell death and demonstrating an EC50 of 8.025 µM. The compounds kb-
NB165-09, kb-NB165-31, and kb-NB184-02 showed similar effects on cell death, with EC50s of 
49.98 µM, 31.91 µM, and 33.84 µM, respectively.   
In addition to the novel analogs demonstrating increased cytotoxicity when compared to 
the parental compound, they also caused dramatic arrest in prostate cancer cell proliferation 
when applied at 10 µM concentration to PC3, CFPAC, and PANC1 cells, as determined by cell 
counts over 6 consecutive days (Figure 20A-C). In contrast to the parental compound, which 
only slowed cell proliferation, the novel analogs markedly inhibited cancer cell proliferation, 
with kb-NB142-70 being most potent among these compounds. 
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Figure 19. Cytotoxic effects of the CID755673 analogs in PC3 cells. PC3 cells were seeded into 96-well plates 
(3000 cells/well) and were then incubated in media containing 0.3-100 µM inhibitors for 72 h. MTT solution was 
added to each well and incubated for 4 h. Optical density was read at 570 nm to determine cell viability. The EC50 
was determined as the mean ± S.E.M. of 3 independent experiments for each compound. 
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Figure 20. Effects of the CID755673 analogs on cancer cell proliferation. The analogs caused potent arrest in 
cancer cell proliferation. PC3 (A), CFPAC (B), or PANC1 (C) cells were plated in triplicate in 24-well plates. The 
next day, cells were counted and the indicated compound was added. Cells were counted daily for a total of 6 days. 
Media and inhibitor were refreshed every 2 days. The mean cell number ± S.E. was plotted over time. The 
experiment was repeated twice and a representative graph is shown. Statistical significance versus Day 1 cell count 
was determined by unpaired t-test for PC3 cells and is indicated. The right panel in (A) is an enlargement of the 
lower portion of the left panel in (A). *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
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To gain insight into the mechanism of growth inhibition caused by the analogs, we 
conducted cell cycle analysis in PC3 cells. Our previous data indicated the parental compound 
CID755673 caused G2/M phase cell cycle arrest when applied at 10 or 25 µM for 6 days 
(Sharlow et al. 2008). In the present study, PC3 cells were treated with 10 µM compound for 48 
h and cell cycle distribution was analyzed by flow cytometry after propidium iodide labeling of 
fixed cells. Indeed, the compounds showed increased accumulation in the G2/M phase of the cell 
cycle when compared to the DMSO treated control or to CID755673 (note that in this 
experiment, 48 h incubation of CID755673 was too short to induce G2/M arrest) (Figure 21). 
Taken together, our data indicate that the novel analogs of CID755673 are efficacious inhibitors 
of survival and proliferation in prostate cancer cells. 
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Figure 21. The analogs cause G2/M phase cell cycle arrest in prostate cancer cells. PC3 cells were treated with 
either vehicle (DMSO) or 10 µM concentration of indicated compound for 48 h. Cell cycle distribution was 
determined by flow cytometry after propidium iodide labeling of fixed cells. G0/G1 and G2/M phases are labeled. 
The experiment was repeated 3 times, and a representative is shown for each compound. 
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3.2.2.6 CID755673 and its analogs cause accumulation of cyclin D1 and cyclin D3  
Though our evidence supports that CID755673 and its analogs induce  cell cycle arrest at G2/M 
phase, a recent study by Torres-Marquez et al. demonstrated that CID755673 treatment enhanced 
phorbol ester- and growth factor-induced DNA synthesis and G1/S cell cycle progression in 
Swiss 3T3 cells independent of PKD1 (Torres-Marquez et al. 2010). In this study, it is important 
to note that both DNA synthesis and cell cycle distribution were determined after 40 h 
CID755673 treatment, while in our previous study cell proliferation was measured by counting 
cell numbers for 6 consecutive days of CID755673 treatment (Sharlow et al. 2008). Although it 
was clear based on counting cell numbers that CID755673 inhibited cell proliferation and 
ultimately caused G2/M arrest, our study did not rule out the possibility that this compound could 
affect other stages of cell cycle progression. To investigate this possibility and to determine if 
CID755673 indeed affects the G1/S transition, we measured the levels of cell cycle markers in 
response to treatment with CID755673 and its analogs. As shown in Figure 22A, CID755673 
induced cyclin D1 and D3 expression in a concentration-dependent manner in PC3 cells, 
suggesting a role for CID755673 in promoting the G1/S transition. Importantly however, the 
analogs of CID755673, with the exception of kb-NB165-09, showed much reduced effects on 
levels of cyclin D1 or D3, implying the specificity of these compounds was improved (Figure 
22B). These data support the idea that CID755673 and its analogs have a complex effect on cell 
cycle progression: in addition to the induction of G2/M arrest and subsequent inhibition of cell 
proliferation, these compounds may also promote the G1/S transition. 
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Figure 22. CID755673 and its analogs cause accumulation of cyclin D1 and cyclin D3. A, PC3 cells were treated 
with increasing concentrations of CID755673 for 48 h. Inhibitor and growth media were refreshed after 24 h. 
Western blots for cyclin D1 and cyclin D3 are shown. B, PC3 cells were treated with 25 µM CID755673, 10 µM kb-
NB142-70, 10 µM kb-NB165-09, 1 µM kb-NB165-92, or 10 µM kb-NB184-02 for 48 h. Note that 1 µM kb-NB165-
92 was used in this assay since this compound at 10 µM caused significant cell death.  Inhibitors and growth media 
were refreshed after 24 h. Western blots for cyclin D1 and D3 are shown. GAPDH was used as a loading control.  
 
3.2.2.7 Effects of the CID755673 analogs on tumor cell migration and invasion  
Previous reports have indicated that PKD may have important roles in the regulation of cell 
motility, adhesion, and invasion (Bowden et al. 1999; Jaggi et al. 2005; Prigozhina and 
Waterman-Storer 2004). Additionally, we previously demonstrated that the PKD inhibitor 
CID755673 slowed cell migration and invasion in prostate and pancreatic cancer cells (Sharlow 
et al. 2008). In order to assess whether the novel analogs of CID755673 retained the ability to 
slow cancer cell migration and invasion, we performed 2 assays. First, we evaluated the effects 
of the compounds on migration in DU145, PC3, and PANC1 cells by wound healing assay. 
Confluent cells were wounded and then treated with either 5 µM or 25 µM inhibitor. Wound 
closure was inhibited in a concentration-dependent manner in all cell lines (Figure 23A-D). In 
this assay, treatment with kb-NB142-70 and kb-NB165-09 resulted in the most dramatic 
reduction in wound healing, with wounds showing only 25-35% closure when treated with 25 
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µM concentration of these two compounds in prostate cancer cells. The effect was a little less 
striking in pancreatic cancer cells, with wounds healing up to 50% when treated with kb-NB142-
70 or kb-NB165-09. The compound kb-NB165-31 appeared to strongly resemble the efficacy of 
the parental compound, demonstrating 55-60% wound closure at 25 µM concentration in both 
PC3 and DU145 cells (Figure 23A-B).  
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Figure 23. Effects of the CID755673 analogs on cancer cell migration. The analogs inhibited wound healing in 
prostate and pancreatic cancer cells. DU145 (A), PC3 (B), or PANC1 (C) cells were grown to confluence in 6-well 
plates. The monolayer was wounded and imaged immediately. Cells were then treated with either vehicle (DMSO) 
or analogs at indicated concentration for 24 h. Cells were then fixed and stained with 0.5% crystal violet. Percentage 
wound closure was calculated as described in “Materials and Methods.” Data shown are the mean ± S.E.M. for 3 
independent experiments. Statistical significance versus the DMSO control was determined by unpaired t-test in 
GraphPad Prism V. ns, not statistically significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001.  
  
86
The analogs also significantly inhibited tumor cell invasion measured by Matrigel 
invasion assay (Figure 24A-B). Consistent with our previously reported results, 10 µM 
CID755673 significantly inhibited invasion of DU145 cells. Invasion was also inhibited by kb-
NB165-31, kb-NB165-92, and kb-NB184-02 at levels similar to the parental compound in 
DU145 cells. However, kb-NB142-70 and kb-NB165-09 showed increased activity in this assay, 
reducing percent invasion to only 10% in DU145 cells. The lead compound kb-NB142-70 
reduced invasion to 20% in CFPAC cells. Taken together, these results support the conclusion 
that the novel analogs of CID755673 significantly inhibit prostate and pancreatic cancer cell 
migration and invasion. 
  
87
A.
0
20
40
60
80
DM
SO
CI
D7
55
67
3
kb
-
NB
14
2-7
0
kb
-
NB
16
5-0
9
kb
-
NB
16
5-3
1
kb
-
NB
16
5-9
2
kb
-
NB
18
4-0
2
DU145
%
 
In
v
as
io
n
***
***
***
***
***
***
     
     
CFPAC
DMSO kb-NB142-70
0
10
20
30
40
50
60
70
80
*
%
 
in
v
as
io
n
C.
 
 
 
 
 
Figure 24. Analogs of CID755673 inhibit cancer cell invasion. A, The analogs inhibited invasion in DU145 cells. 
0.08 x 106 DU145 cells in RPMI 1640 media containing 0.1% FBS and 10 µM of indicated compound were seeded 
into Matrigel inserts. After 22 h, noninvasive cells were removed and invasive cells were fixed in 100% methanol, 
stained in 0.5% crystal violet solution, and photographed. The number of cells that invaded the Matrigel matrix was 
determined by cell counts in at least 5 fields relative to the number of cells that migrated through the control insert. 
The data shown is the mean ± S.E.M. of 3 insert samples from 2 independent experiments (n = 6 per sample). 
Statistical significance versus the control DMSO was determined by unpaired t-test. ***, p < 0.001. B, 
Representative images comparing invasion of the vehicle (DMSO) and the compounds. C, The lead compound kb-
NB142-70 inhibited invasion in CFPAC pancreatic cancer cells. The invasion assay was performed as above using 
10 µM kb-NB142-70. The data shown is the mean ± S.E.M. of 3 insert samples from 2 independent experiments (n 
= 6 per sample). 
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3.2.2.8 A CID755673-derived photoaffinity-labeling compound inhibits PKD in vitro and in 
cells 
To assist in elucidating the mechanism of action of CID755673 and its analogs, a series of 
photoaffinity-labeling compounds derived from a CID755673-based scaffold were synthesized in 
the laboratory of Dr. Peter Wipf (see Appendix A, Table 6, Entries 1–4). This series of analogs 
included modifications that would, in theory, allow for irreversible binding of the compound to 
PKD, facilitating subsequent determination of the binding site and providing insight into the 
mechanism through which these compounds inhibit PKD. We analyzed the in vitro activity of 
these compounds by radiometric kinase assay. Notably, the azide analog MCF292-08 retained 
high inhibitory activity toward PKD1 (IC50 = 74.9 nM, Figure 25A-B). Cellular activity was also 
comparable to the novel analogs, with a cellular IC50 of 2.2 µM toward inhibition of PMA-
induced Ser916-PKD1 autophosphorylation in LNCaP cells (data not shown). Furthermore, initial 
investigations suggested that exposure to UV light resulted in irreversible binding of MCF292-08 
to PKD1 in vitro, and enhanced inhibitory activity in cells (data not shown). Based on these 
encouraging results, ongoing studies that utilize this novel compound to elucidate the mechanism 
of PKD inhibition by this class of compounds are currently being conducted.  
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Figure 25. The photoaffinity-labeling compound MCF292-08 inhibits PKD1 in vitro. A, chemical structure of 
MCF292-08. B, PKD kinase activity was assayed by a radiometric kinase assay in the presence of increasing 
concentrations of MCF292-08. A 10-point concentration curve was generated for IC50 determination. The IC50 was 
determined by taking the mean ± S.E.M. of 5 independent experiments with triplicate determinations at each 
concentration in each experiment. A representative graph is shown. 
 
 
3.3  DISCUSSION 
 
In 2008, we reported the identification and characterization of CID755673, a 
benzoxoloazepinolone that inhibited all 3 isoforms of PKD with an IC50 of around 200 nM 
(Figure 4) (Sharlow et al. 2008). This significant discovery of the first potent, specific PKD 
inhibitor paved the way for the surge of additional novel PKD inhibitors which hit the literature 
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in the 2-3 years following our publication of CID755673 (Harikumar et al. 2010; LaValle et al. 
2010a; Monovich et al. 2009; Raynham et al. 2008; Singh et al. 2009).  
Our subsequent studies detailed the characteristics of PKD inhibition that CID755673 
and its analogs demonstrated. CID755673 indeed showed some specificity toward PKD over 
several related kinases, and it did not inhibit the in vitro activity of PKCα, PKCβ, PKCδ, or 
CaMKIIα. Unlike the majority of commonly-used kinase inhibitors, CID755673 appeared to 
have a unique mechanism of action, inhibiting PKD1 in a non-ATP- and non-substrate-
competitive fashion. Importantly, CID755673 retained cellular activity, albeit with a lower 
potency, inhibiting PKD1 autophosphorylation with an apparent IC50 of around 10 µM. Cellular 
studies also revealed that CID755673 reduced cell proliferation, migration, and invasion in 
prostate ans pancreatic cancer cells, highlighting the potential significance of the novel chemical 
structure in future drug development.  
As mentioned, the evolving literature has revealed the discovery of several additional 
novel PKD inhibitors in recent years (Harikumar et al. 2010; LaValle et al. 2010a; Monovich et 
al. 2009; Raynham et al. 2008; Singh et al. 2009). In addition to CID755673 and its analogs, an 
interesting bipyridyl, BPKDi (2'-(cyclohexylamino)-6-(piperazin-1-yl)-[2,4'-bipyridine]-4-
carboxamide), was recently identified  as a very potent inhibitor of PKD1, -2, and -3 (IC50 of 1-9 
nM) in a >650,000 compound high-throughput screen (Figure 26) (Monovich et al. 2009). 
BPKDi had very little or no activity toward CaMKIδ, CaMKIIα, CaMKIIβ, CaMKIIδ, CaMKIV, 
MARK1, MARK2, SIK1, GRK5, PKCδ, or PKCε. The compound caused substantial inhibition 
of PKD1 autophosphorylation at 1 µM concentration. Furthermore, treatment of cardiac 
myocytes with BPKDi resulted in reduced phosphorylation and increased nuclear retention of 
HDAC4 and HDAC5, validating these proteins as PKD substrates.  
  
91
N
N
N
H
N
N
H
O
H2N
BPKDi
 
Figure 26. Chemical structure of BPKDi. This compound was discovered to be a potent and selective active site 
inhibitor of PKD. 
 
Additional inhibitors emerging in the literature include a class of amino-ethyl-amino-aryl 
compounds 1, 2, and 3 (Figure 27) (Raynham et al. 2007).  Compound 1 was shown to inhibit 
PDBu-stimulated PKD1 Ser916 phosphorylation in PANC-1 cells with an IC50 of 4 µM, while 
compounds 2 and 3 showed inhibition of PKD1 in the low and sub-nanomolar range, 
respectively. Additionally, compound 3 was reported to inhibit PKD2 with an IC50 of 4.1 nM.  
Furthermore, the pyrazine and pyridine benzamides 5 and 6 were reported to be inhibitors of 
PKD1 with low nanomolar IC50 values. Benzamides 4 and 6 were similarly potent, exhibiting 
IC50 values of 420 nM and 32 nM, respectively, against PKD1 (Raynham et al. 2008).  
Compounds containing the pyrimidinediamine scaffold, such as compound 7, also demonstrated 
potent inhibition of PKD in the low nanomolar range (Singh et al. 2009). Another pan-PKD 
inhibitor, CRT0066101 (Figure 27, compound 8), was reported very recently (Harikumar et al. 
2010). CRT0066101 inhibits PKD1, PKD2, and PKD3 with in vitro IC50s of 1, 2.5, and 2 nM, 
respectively, and has a cellular IC50 of 0.5 µM for PKD1 in intact PANC-1 cells. The structure of 
CRT0066101 appears to be derived from the core structure of compounds 1, 2, and 3 (Figure 
27). The interesting scaffold 8 was reported to inhibit cell proliferation, induce apoptosis, and 
reduce viability of pancreatic cancer cells. Furthermore, treatment with CRT0066101 was shown 
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to affect levels of PKD biomarkers including phosphorylated Hsp27, activated NFκB, and 
expression of NFκB-regulated genes. The most attractive features of this inhibitor are that it is 
orally available and efficacious in vivo. CRT0066101 given orally at 80 mg/kg/d significantly 
suppressed the growth of subcutaneous (qd for 24 days) and orthotopic (qd for 21 days) 
pancreatic tumor xenografts in mice. This study provides strong support for targeting PKD in 
pancreatic cancer therapy (Harikumar et al. 2010), and the efficacy of this compound in other 
tumor types awaits further evaluation. Taken together, efforts at developing PKD-selective 
inhibitors have so far consistently demonstrated PKD as an effective target for cancer therapy. 
N
N
HN
NH2
Cl
HO
N
N
HN
NH2
OH
Cl
N
N
N
NH2
Cl
HO
N
N
HO
O O NH
N
N
HO
O O NH
H2N N
HO
O O NH
H2N
N
N
N
H
N
H
F3CN
CF3
N
N
N N N
1 2
4
3
5 6
7 HO
R3
N
N
N
R2
R1 NH2
8
 
Figure 27. Recent active site PKD inhibitors reported in the literature. 
 
It is important to note that both CID755673 and BPKDi were identified using PKD1 
biochemical high throughput screens (Monovich et al. 2009; Sharlow et al. 2008) and display 
inhibitory activity against all 3 PKD isoforms. The individual screening strategies (i.e., PKD 
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isoform and substrate pairing) used to identify these small molecule inhibitors may have directly 
impacted the specificity (or lack thereof) of the identified chemotypes. A more advantageous 
strategy may focus on a particular PKD-isoform paired with its isoform-specific substrate. As 
our understanding of the roles of each PKD isoform expands, and with the emergence of 
isoform-specific substrates, this strategy may prove to be more advantageous. 
The novel analogs of CID755673, synthesized to have modifications in both the core 
structure and side chains, showed equal or increased potency to PKD1 inhibition in vitro and in 
cells when compared with CID755673. Additionally, we confirmed they also inhibited PKD2 
and PKD3 in vitro, acting as pan-PKD inhibitors like the parental compound. Of the compounds 
reported here, the most potent was kb-NB142-70, which inhibited PKD1 with nearly a 7-fold 
greater potency compared to the parental compound. Furthermore, kb-NB142-70 inhibited PKD2 
and PKD3 with about 4-fold increased potency than CID755673. The analogs also demonstrated 
increased inhibition of PMA-induced autophosphorylation of endogenous PKD1 in LNCaP 
prostate cancer cells when compared to the parental compound. In fact, the new lead compound, 
kb-NB142-70, was found to inhibit PKD1 with an IC50 of 28 nM in vitro and shows significantly 
increased cellular activity, inhibiting PKD1 autophosphorylation at Ser916 with an IC50 of around 
2 µM in LNCaP cells. Thus, we have established that these small molecule analogs of 
CID755673 are also potent inhibitors of PKD both in vitro and in cells.  
 CID755673 is superior in specificity when compared with other  compounds known to 
inhibit PKD, such as staurosporine and staurosporine-related the compounds K252a and Gö6976, 
even though these compounds have been reported to inhibit PKD in the low double- and single-
digit nanomolar range (IC50s of 40 nM, 7 nM, and 20 nM, respectively). This specificity may 
stem from the unique mechanism of action of CID755673 (Table 2). Though the exact 
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mechanism through which CID755673 and its analogs inhibit PKD has not yet been elucidated, 
we have shown that CID755673 is both non-ATP- and non-substrate-competitive. Ongoing 
studies utilitzing the novel photoaffinity-labeling compound MCF292-08 may provide 
significant insight into the mechanism of action of this class of compounds, including elucidation 
of the inhibitor binding site.  
A kinase profiling report demonstrated that CID755673 may also target a few additional 
kinases, including GSK3β, CK1δ, MK5, MK2, ERK1, and CDK2. Importantly however, 
CID755673 lacks or shows only marginal activity towards almost all PKC isoforms that have 
been tested thus far (including PKC-α, -β, -γ, -δ, -η, -θ and -ζ), which distinguishes it from 
commonly used PKC/PKD inhibitors such as Gö6976. This feature may allow selective targeting 
of PKD-mediated signaling pathways and cellular processes, though discretion must be used 
since additional targets of CID755673 do indeed exist. Furthermore, when making conclusions 
as to the functional role of PKD in such cellular processes as proliferation, growth, and motility 
as presented here, it is important to confirm the results of inhibitor studies using specific PKD-
targeting siRNA or shRNA. In previous studies published in our laboratory and in Chapter 4 of 
this dissertation, we demonstrated that transient PKD3 knockdown using specific PKD3-
targeting siRNA and stable, inducible knockdown using specific shRNA vectors caused arrest in 
PC3 cell proliferation (Chen et al. 2008). Additionally, in Chapter 4 of this dissertation, we 
provide evidence that knockdown of PKD2 and PKD3 using siRNA or shRNA reduces 
migration and invasion, similar to the observed effects of our novel PKD inhibitors. Thus, we 
can conclude that the effects of our novel pan-PKD inhibitors on prostate cancer cell 
proliferation, migration, and invasion are at least in part due to inhibition of PKD.  
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Similar to the parental compound, the novel analogs for the most part retained specificity 
when tested against PKCα, -βI, -δ, and CAMKIIα. One compound, kb-NB165-31, did show 
significant inhibitory activity toward PKCδ and CAMKIIα when tested at 10 µM concentration. 
This compound has an iodine atom added as a side chain of the benzene ring in kb-NB142-70, 
which retained strong selectivity to PKD in vitro, suggesting that the increase in lipophilicity and 
the introduction of a polarizable group at the phenol ortho-position reduce compound specificity. 
Interestingly, in the case of kb-NB165-92, the expansion of the lactam by one carbon to a fused 
8-membered ring reduced the potencies for PKD1 and PKD2 by 2-4 fold, while not altering 
potency for PKD3, implying that zone III of our pharmacophore may contain determinants for 
isoform-selectivity. However, this concept should be further exploited as methoxy analogs of kb-
NB142-70 and kb-NB165-92, in contrast, did not exhibit an analogous shift in isoform-
selectivity. 
 Cellular activity of the analogs was demonstrated through inhibition of PMA-induced 
activation of endogenous PKD1 by measuring the phosphorylation levels of Ser916 and Ser742. 
Based on the canonical pathway of PKC-dependent PKD activation, phorbol ester-stimulated 
phosphorylation on Ser738/742 by PKC followed by autophosphorylation of PKD1 on Ser916 would 
result in full activation of PKD (Matthews et al. 1999; Waldron et al. 1999; Waldron et al. 2001; 
Zugaza et al. 1996). However, studies have also suggested that Ser742 may be a site of both trans- 
and autophosphorylation. While initial, early catalytic activation of PKD requires rapid 
transphosphorylation on Ser738/742 by PKC isoenzymes, and can be blocked by the PKC 
inhibitors Gӧ6983 and GF 109203X, the major mechanism required to maintain prolonged PKD 
activation is PKC-independent and relies on autophosphorylation at Ser742 (Jacamo et al. 2008). 
Therefore, since in vitro studies failed to show inhibition of any PKC isoform tested, we can 
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conclude that the observed dose-dependent inhibition of Ser742 phosphorylation on PKD1 after 
agonist stimulation (100 nM PMA for 20 min) by our novel PKD inhibitors likely reflects the 
inhibition of PKD1 autophosphorylation at this site, analogous to the inhibition of Ser916 
phosphorylation. Further analysis is required to determine the precise mechanism of inhibition of 
PKD by these novel compounds and to investigate the kinetics of PMA-induced Ser916 and Ser742 
phosphorylation of PKD1 in the presence of these inhibitors, which may further establish Ser742 
as an additional autophosphorylation site and confirm the specificity of these inhibitors to PKD.  
PKD has been implicated in the regulation of cell proliferation, survival, and apoptotic 
pathways in multiple cell types (Chen et al. 2008; Storz 2007; Trauzold et al. 2003). We have 
previously shown that PC3 cells predominantly express high levels of PKD3, potentially making 
them very sensitive to PKD3 inhibition, and that knockdown of PKD3 by siRNA causes strong 
arrest in cell proliferation in these cells (Chen et al. 2008). Here, we have shown that one of the 
more striking differences between the parental compound and its analogs is the increase in 
cytotoxicity and dramatic arrest in cell proliferation. While CID755673 is only minimally 
cytotoxic to prostate cancer cells, and can be tolerated at high concentrations for prolonged 
treatments (Sharlow et al. 2008), the novel analogs induced significant cytotoxicity in PC3 cells 
after much shorter treatments (48 h) and at much lower concentrations (5-10 µM). Based on our 
preliminary analysis, the effects of the compounds on viability in other prostate cancer cells 
(LNCaP and DU145) are comparable to those in PC3 cells (data not shown). The inhibitors 
appear to exhibit a general inhibitory effect on cell viability, with efficacy varying between 
different tumor cell types. Additionally, the analogs cause much more dramatic arrest in cell 
proliferation than the parental compound. This improvement in the antiproliferative effects of the 
analogs was accompanied by lowered IC50s for PKD1 inhibition in LNCaP cells (2.2 µM for the 
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new lead compound, kb-NB-142-70, versus ~10-30 µM for the parental compound, CID755673). 
Moreover, since the antiproliferative effects of the analogs phenocopied those caused by 
knockdown of PKD3 in PC3 cells (Chen et al. 2008), it is conceivable that these effects, at least 
to some extent, are mediated through inhibition of PKD. That said, we cannot exclude the 
possibility that CID755673 and its analogs have additional cellular targets whose inhibition may 
contribute to the elevated cytotoxicity and potent growth arrest observed in prostate cancer cells. 
Furthermore, since the analogs, mimicking the parental compound, all induced apparent G2/M 
cell cycle arrest, it is likely that the mechanisms underlying the growth inhibition caused by the 
analogs are similar to those induced by the parental compound.  
Although CID755673 and its analogs potently inhibited cell proliferation, their effects on 
cell cycle progression appeared to complex, involving two opposing effects on different stages of 
the cell cycle: 1) promotion of the G1/S transition; 2) induction of G2/M arrest. The G2/M arrest 
ultimately leads to cessation of cell proliferation. However, the complexity of these effects is still 
not understood. In a recent study, CID755673 was found to enhance PDBu- and growth factor-
stimulated DNA synthesis and G1/S cell cycle transition independent of PKD1 in Swiss 3T3 cells 
(Torres-Marquez et al. 2010). Given that this report by Torres-Marquez et al. used DNA 
synthesis and cell cycle distribution as readouts, it remains to be determined if the potentiation 
effect reported indeed resulted in increased cell number (cell proliferation) in their assays since 
the G2/M block may ultimately inhibit this effect. With regard to the potential targets that may 
account for this effect, we hypothesize, based on our kinase profiling data, that GSK-3β could 
play a role since active GSK-3β has a negative effect on cell cycle progression (Takahashi-
Yanaga and Sasaguri 2008). Expression of the cell cycle proteins cyclin D1 and cyclin D3 is 
regulated by GSK-3β signaling at the transcriptional level and through protein degradation (De 
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Santa et al. 2007; Naderi et al. 2004; Takahashi-Yanaga and Sasaguri 2008). Thus, inhibition of 
GSK-3β may be in part responsible for the promotion of the G1/S transition and the reported 
potentiation effect with other mitogens and may also explain our observed concentration-
dependent increase in cyclin D1 and cyclin D3 levels with CID755673 treatment in prostate 
cancer cells (Figure 22) (LaValle et al. 2010a; Torres-Marquez et al. 2010). Additionally, since 
the analogs in general do not cause significant induction of cyclins D1 and D3 compared to the 
parental compound (Figure 23), they may not have mitogenic effects like CID755673 (Torres-
Marquez et al. 2010), in part explaining the significantly increased effects of these novel analogs 
on arrest of cell proliferation. It is clear, however, that despite these unintended effects in our 
experimental system, the ultimate cell fate, i.e. cell growth arrest and subsequent cell death, was 
not altered.  
Clearly, these new findings suggest that this class of compounds may target additional 
proteins, resulting in complex effects on cell cycle progression. Based on this kinase profiling 
data, we speculate that, in addition to PKD, the inhibitory effect of CID755673 and its analogs 
on cell proliferation may be contributed to the inhibition of CDK2, another potential target of 
CID755673. Although CDK2 is generally considered a regulator of S-phase entry (Bashir and 
Pagano 2005; Hu et al. 2001), some reports have also linked it to the G2/M transition (Hu et al. 
2001; Wang et al. 1997). According to the accepted model of cell cycle progression, CDK2 is 
activated by binding to cyclin E in late G1 phase, resulting in phosphorylation of the 
retinoblastoma protein (Rb) and facilitating the G1/S-phase transition (Satyanarayana and Kaldis 
2009). It also promotes progression of S-phase by binding to cyclin A. However, it has been 
reported that inhibition of CDK2 by expression of a dominant negative CDK2 mutant or 
overexpression of p27kip1 can cause accumulation in G2/M (Hu et al. 2001; Wang et al. 1997). 
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Therefore, it is plausible that the G2/M arrest and reduced cell proliferation caused by 
CID755673 and its analogs is in part due to inhibition of CDK2. It is also possible that 
CID755673 and its analogs may inhibit other members of the CDK family, for example CDK1, 
which plays a critical role in G2/M cell cycle progression.  
In addition to CDK2, casein kinase 1 delta (CK1δ) was also identified as a potential 
target of CID755673. This kinase belongs to a family of serine/threonine kinases that regulate a 
variety of cellular processes, including cell cycle progression, Wnt singaling, and the DNA 
damage response, and has been implicated in the progression of pancreatic cancer (Brockschmidt 
et al. 2008; Knippschild et al. 2005; Price 2006). Studies have shown that inhibition of CK1δ and 
CK1ε using the selective inhibitor IC261 resulted in dramatic arrest in pancreatic cancer cell 
growth and was accompanied by G2/M cell cycle arrest (Brockschmidt et al. 2008). However, 
subsequent investigations have shown that IC261 can induce cell cycle arrest via regulation of 
the mitotic spindle at much lower concentrations than those required to inhibit CK1δ, therefore 
contesting whether CK1δ is indeed involved in regulating G2/M arrest (Cheong et al. 2011), and 
studies demonstrating specific effects of CK1δ knockdown on cell cycle arrest are still lacking 
(Brockschmidt et al. 2008; Cheong et al. 2011; Cheong and Virshup 2011).  
Finally, it must be stated that although CKD2, CK1δ, and a few other proteins were 
identified as potential hits in a single dose kinase profiling experiment (Table 5), the activities of 
CID755673 and its analogs toward these targets need to be further validated in 10-point dose-
response kinase assays, and, more encouragingly, the activity profile of new analogs of 
CID755673 shows reduced off-target effects to accompany the markedly increased efficacy in 
tumor cells (Figure 22) (LaValle et al. 2010a). 
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 In addition to the effects of these analogs on cell survival and proliferation, we also show 
that they are significant inhibitors of cancer cell migration and invasion. The compounds kb-
NB142-70 and kb-NB165-09 in particular, strongly reduced wound healing in DU145, PC3, and 
PANC1 cells in a dose-dependent manner, and significantly inhibited invasion of DU145 and 
CFPAC cells through Matrigel invasion inserts when applied at 10 µM concentration. 
Furthermore, the pattern of inhibition exhibited by the analogs is fairly consistent with their 
inhibitory activities toward PKD. This suggests an important role for PKD in prostate and 
pancreatic cancer cell motility and supports the potential value of therapeutic targeting of PKD in 
the reduction or prevention of tumor metastases. Though the mechanism through which PKD 
may mediate migration and invasion is not yet known, several recent reports have begun to shed 
light onto the complexity of these signaling pathways, suggesting PKD involvement in both β-
catenin and Akt signaling in prostate cancer cells (Chen et al. 2008; Jaggi et al. 2003; Jaggi et al. 
2005). 
In conclusion, we report the biochemical and functional analysis of CID755673 and 
several of its analogs. These analogs show equal and increased potency toward PKD inhibition 
both in vitro and in cells. The new lead compounds display prominent cytotoxic and anti-
proliferative effects, and potently inhibit migration and invasion in prostate and pancreatic 
cancer cells. Although the molecular mechanisms underlying some of the biological effects of 
these compounds appear to be complex and may involve additional targets, their potent effects 
on multiple cancer-associated biologies warrant further development of this series of compounds 
toward possible clinical application in cancer therapy. 
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4.0  ANALYSIS OF THE FUNCTIONAL ROLE OF PROTEIN KINASE D IN 
PROSTATE CANCER 
 
 
4.1  INTRODUCTION 
 
Prostate cancer is the second leading cause of cancer-related death in men in the United States 
and the number one cause of death in men over age 75 (Jemal et al. 2009). Tumors arise in the 
prostate gland, a walnut-sized structure that wraps around the urethra, and may grow slowly, 
remaining benign for many years, or may grow rapidly and metastasize, leading to serious 
complications and even death (Jadvar 2011). Advances in screening procedures have resulted in 
earlier diagnosis; however, the benefits of catching this disease in its early stages remains a 
controversial topic (Cook and Nelson 2010; Shirai 2008). In particular, the discovery of prostate-
specific antigen (PSA) as a serum marker for the detection of prostate carcinoma, and the 
development of screening procedures to measure PSA levels, have significantly increased early 
diagnosis (Cook and Nelson 2010; Zaviacic 1997). Still, despite early interventions and 
chemopreventive measures, therapeutic options are limited once the prostate tumor has 
metastasized (Shirai 2008). A more complete understanding of the molecular mechanisms 
underlying prostate cancer progression is necessary to facilitate the development of novel 
therapies. 
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In relatively recent years, the PKD family of serine/threonine kinases has been the subject 
of a variety of studies focusing on prostate cancer progression (LaValle et al. 2010b). These 
studies date back as early as 2003, when Balaji and colleagues reported that PKD1 appeared to 
be down-regulated in androgen-independent prostate cancer (Jaggi et al. 2003). Additional 
evidence from this same research group began to emerge showing that PKD1 was involved in 
regulating prostate cancer cell growth and motility, acting primarily as a tumor-suppressor 
(Biswas et al. 2010; Du et al. 2009; Jaggi et al. 2005; Mak et al. 2008; Syed et al. 2008). In 2008, 
our laboratory began to investigate PKD function in the context of prostate cancer. We showed 
that levels of PKD3, the least-studied of the PKD isoforms, were elevated in human prostate 
tumor tissues (Chen et al. 2008). Increased nuclear localization of PKD3 was found to be 
correlated with tumor grade, suggesting hyperactivity of this isoform in advanced prostate cancer 
(Chen et al. 2008). Furthermore, in cellular studies, our lab reported that transient knockdown of 
PKD3 reduced prostate cancer cell growth, likely through an Akt-mediated signaling pathway 
(Chen et al. 2008). The differential expression and distinct functions of the PKD isoforms 
apparent from these studies emphasizes the complexity of cancer pathology and progression, and 
underlies the need to elucidate the specific signaling events and molecular mechanisms involved 
in these processes.  
As a Golgi resident protein, PKD has been shown to be essential for membrane fission 
and vesicle formation in the transport of cargo from the trans-Golgi network (TGN) to the 
plasma membrane (Bossard et al. 2007; Liljedahl et al. 2001; Malhotra and Campelo 2011). 
Although the mechanisms through which PKD regulates protein trafficking have been well 
studied, little is known of the identity of transported cargo, and the relevance of this regulation to 
tumor development remains to be determined. PKD1, the subject of the majority of studies on 
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PKD function, has been implicated in the secretion of several tumor-promoting cytokines such as 
IL-6, IL-8, and GROα/CXCL-1 (Hao et al. 2009; Ochi et al. 2011; Steiner et al. 2010), and 
matrix metalloproteinases (MMPs), secreted endopeptidases that play a major role in the 
degradation of the extracellular matrix (Biswas et al. 2010; Eiseler et al. 2009a; Lokeshwar 
1999). However, it remains to be determined 1) how PKD regulates these processes, 2) whether 
these regulatory mechanisms affect tumor growth, and 3) what the functions of the other PKD 
isoforms are in modulating these events. 
In this report, we provide substantial evidence for a tumor-promoting role for PKD3 in 
prostate cancer progression. Our results demonstrate that PKD3 modulates proliferation and 
motility of prostate cancer cells. Furthermore, we demonstrate that PKD3 mediates the secretion 
of multiple factors that stimulate cancer progression in multiple prostate cancer cell lines. These 
data validate PKD3 as a novel therapeutic target in the treatment of prostate cancer, and broaden 
our current understanding of the molecular mechanisms of PKD function in cancer progression. 
 
 
 
4.2  RESULTS 
 
4.2.1  Development of a stable, tetracycline-inducible PKD3 knockdown prostate cancer 
cell line 
 
We have previously demonstrated that PC3 cells express high levels of PKD3, moderate PKD2, 
and no detectable PKD1 (Chen et al. 2008). Additionally, PKD3 was found to be overexpressed 
in human prostate tumors, highlighting the potential contribution of this isoform to prostate 
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cancer progression (Chen et al. 2008). Therefore, to facilitate the further study of PKD3 function 
in prostate cancer, we developed a PC3 cell line stably expressing a tet-inducible shRNA 
targeting PKD3 (Figure 28). In this model, PC3 cells express the tet-repressor (TR). In its 
unstimulated state, the TR binds to the promoter region, called the tet-operon (TO), of the 
integrated plasmid DNA, repressing transcription of the shRNA. When tetracycline (tet) is 
applied to the cells, the tet binds to the TR, causing dissociation of the TR from the TO, and 
allowing expression of the shRNA. Four stable clones were isolated that showed downregulation 
of PKD3 upon 5-day treatment with 1 µg/mL tet: shPKD3-1 C7, shPKD3-1 C26, shPKD3-1 C2-
1, and shPKD3-1 C2-3. A clone expressing non-targeting, scrambled shRNA (shScr) was also 
isolated. Western blotting analysis revealed 50-75% knockdown of PKD3 protein levels from the 
isolated shPKD3-1 clones after 5-day tet treatment (Figure 29A). PKD3 levels of the shScr 
clone were unaffected. PKD2 levels were also unchanged in the tet-treated cells for all clones, 
evidence that our shRNA targeted specifically the PKD3 isoform. For further confirmation of the 
knockdown, we performed RT-qPCR analysis. With this method, we observed 50% and 65% 
reduction in PKD3 transcript levels for clones shPKD3-1 C2-1 and shPKD3-1 C2-3, respectively 
(Figure 29B). 
PKD3 
shRNA
TR PKD3
tet
 
 
Figure 28. Model of tetracycline-inducible PKD3 knockdown. PC3 cells expressing the tet-repressor (TR) were 
transfected with the vector containing shRNA targeting PKD3 and stable cell lines were generated. Upon treatment 
with 1 µg/mL tetracycline, the PKD3 shRNA is expressed and PKD3 expression is reduced. 
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Figure 29. Tetracycline-induced knockdown of PKD3. PC3-TR cells were transfected with the pENTR/TO/H1 
vector containing shRNA targeting PKD3, as described in “Materials and Methods.” After stable selection, clones 
were treated with 1 µg/mL tet for up to 5 days. Cells were collected and PKD3 expression was analyzed by Western 
blotting (A) and RT-qPCR (B). Densitometry analysis of the Western blotting results is shown as the mean ± S.E.M. 
of 3 independent experiments. Statistical significance is indicated (*, p < 0.05; **, p < 0.01; ***, p < 0.001). 
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4.2.2.  Tetracycline-induced knockdown of PKD3 reduces prostate cancer cell 
proliferation, migration, and invasion 
 
Next, we wanted to determine the effects of PKD3 knockdown on several significant cancer-
related phenotypes. We first investigated whether tet-induced knockdown of PKD3 caused a 
reduction in cell proliferation in this model system. After a 5-day pretreatment with 1 µg/mL tet, 
the number of viable cells was determined each day for 6 days.   
As shown in Figures 30A-F, each of the 4 stable PKD3 knockdown clones showed a 
significant reduction in cell proliferation, whereas growth of both the parental PC3-TR cell line 
and the shScr clone were unaffected by tet treatment. This is consistent with our previous report 
that transient knockdown of PKD3 by siRNA causes a significant decrease in proliferation in 
PC3 cells (Chen et al. 2008). 
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Figure 30. Tetracycline causes reduced proliferation in stable shPKD3-1 clones. PC3-TR (A), shScr (B), 
shPKD3-1 C7 (C), shPKD3-1 C26 (D), shPKD3-1 C2-1 (E), or shPKD3-1 C2-3 (F) cells were pre-treated with 1 
µg/mL tet for 5 days then replated at 5000 cell/well in 24-well plates. Cell number was determined every day for up 
to 6 consecutive days. Media and tet were refreshed every 2 days. Experiments were repeated 3 times, and a 
representative graph is shown. 
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Cell motility is essential for the acquired ability of cancer cells to invade into surrounding 
tissue and form distant metastases, a key step in the progression of aggressive prostate cancer 
(Lee and Tenniswood 2004). To date, the role of PKD3 in prostate cancer cell motility has not 
been described. Therefore, we investigated whether tet-induced knockdown of PKD3 could alter 
cell migration and invasion. After a 5-day induction with 1 µg/mL tet, we performed a wound 
healing assay to measure cell migration using our stable clones and the shScr control. While the 
“wound” completely closed in both the parental PC3-TR cell line and the shScr cells, wound 
closure was reduced to only 45% and 35% in the PKD3 knockdown clones shPKD3-1 C7 and 
shPKD3-1 C26, respectively (Figure 31A-B). This result was further confirmed using transient 
knockdown of PKD2 and/or PKD3 by siRNA in PC3 cells, which resulted in nearly a 60% 
reduction in wound healing compared to the non-targeted siRNA control (Figure 32A-B). 
Interestingly, there did not appear to be an additive effect of the dual PKD2/PKD3 knockdown in 
this experiment, suggesting that these 2 isoforms may have non-redundant functions and may act 
on distinct pathways. However, it is also possible that a 60% decrease in wound healing is the 
maximum that can be achieved in this cell line under these conditions and any additive effects 
may not be able to be demonstrated.    
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Figure 31. Inducible knockdown of PKD3 leads to reduced cell migration. PC3-TR, shScr, shPKD3-1 C7, or 
shPKD3-1 C26 cells were pre-treated with 1 µg/mL tet for 5 days, and then replated in 6-well plates. After growing 
to confluence, the monolayer was wounded using a 10 µL pipette tip, and an image was taken immediately. Twenty-
four hours later, cells were fixed in methanol and stained with 0.5% crystal violet. A final image was taken (A), and 
the percent wound healing was calculated as described in the “Materials and Methods.” The experiment was 
repeated 3 times. Data are the mean percent wound healing ± S.E.M. as determined from 3 separate measurements 
of the wound area from 3 independent experiments (B). Statistical significance is indicated (***, p < 0.001). 
Representative images are shown (A).  
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Figure 32. Transient knockdown of PKD2 and/or PKD3 reduces migration in PC3 cells. PC3 cells were 
transiently transfected with non-targeting siRNA (siNT) or siRNA targeting PKD2 (siPKD2), PKD3 (siPKD3), or 
both PKD2 and PKD3 (siPKD2+3). Two days later, cells were replated in 6-well plates and grown to confluence. 
Wound-induced migration was measured as described in the “Materials and Methods.” Representative images at 0 h 
(top panels) or 18 h (bottom panels) are shown (A). The graph depicts the mean ± S.E.M. of 3 separate 
measurements of the wound area from 3 independent experiments (B).  
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In order to measure the effects of PKD3 knockdown on the ability of cells to invade, we 
performed a Matrigel invasion assay using our stable clone shPKD3-1 C7 and the shScr control 
cells. After a 5-day induction with tet, we replated the cells into the top chambers of Matrigel 
invasion inserts, in the presence or absence of tet. Twenty percent FBS was used in the bottom 
chamber as a chemoattractant. Our data showed that invasion of the tet-treated shPKD3-1 C7 
cells was reduced to only 20%, compared to 65% invasion for the non-treated shPKD3-1 C7 
cells (Figure 33). Invasive capacity of the shScr cells was not affected by the addition of tet. 
This result was again further confirmed using a transient knockdown of PKD2 and/or PKD3 
(Figure 34). Taken together, these data demonstrate a novel role for PKD3 and PKD2 in the 
modulation of prostate cancer cell motility, a key capacity required for the progression and 
metastasis of aggressive prostate cancer. 
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Figure 33. Tetracycline-induced PKD3 knockdown reduces invasion in PC3 cells. After pretreatment for 5 days 
with 1 µg/mL tet, 0.08M shScr or shPKD3-1 C7 cells in Ham’s F12 media containing 0.1% FBS were seeded into 
Matrigel invasion or control inserts. Twenty percent FBS was added to the bottom chamber to stimulate invasion. In 
tet-treated cells, 1 µg/mL tet was added to both the top and bottom chambers. After 22 h, noninvasive cells were 
removed and invasive cells were fixed in 100% methanol, stained in 0.1% crystal violet solution, and photographed. 
The number of cells that invaded the Matrigel matrix was determined by cell counts in at least 5 fields relative to the 
number of cells that migrated through the control insert. A, Representative images comparing the invasiveness of 
shScr and shPKD3-1 C7 cells with and without tet are shown. B, The graphs show the mean ± S.E.M. of 3 
independent experiments, each run in triplicate. Statistical significance versus the untreated control was determined. 
***, p < 0.001.  
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Figure 34. Transient knockdown of PKD2 and/or PKD3 reduces PC3 cell invasion. PC3 cells were transiently 
transfected with siRNAs targeting PKD2 (siPKD2), PKD3 (siPKD3), or both PKD2 and PKD3 (siPKD2+3). As a 
control, cells were transfected with non-targeting siRNA (siNT). Forty-eight hours following transfection, cells were 
replated into Matrigel invasion or control inserts at 0.08M cells/well in Ham’s F12 media containing 0.1% FBS. 
Twenty percent FBS was added to the bottom chamber to act as a chemoattractant. After 22 h, noninvasive cells 
were removed and invasive cells were fixed in 100% methanol, stained in 0.1% crystal violet solution, and 
photographed. The number of cells that invaded the Matrigel matrix was determined by cell counts in at least 5 
fields relative to the number of cells that migrated through the control insert. The data shown is the mean ± S.E.M. 
of 3 independent experiments, each run in triplicate. Statistical significance versus the untreated control was 
determined by unpaired t-test. *, p < 0.05; **, p < 0.01. 
 
4.2.3  PKD3 knockdown leads to reduced secretion of MMPs 
 
As a major traffic regulator, PKD has been shown to regulate cell motility through modulation of 
anterograde membrane traffic from the TGN to the plasma membrane (Prigozhina and 
Waterman-Storer 2004), which we hypothesized may impact the secretory pathways in tumor 
cells. Here, we investigated whether secreted factors may be involved in the PKD-mediated 
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regulation of PC3 cell migration. Indeed, we found that the conditioned medium collected from 
tet-treated shPKD3-1 C7 cells exhibited a significantly reduced capacity to promote PC3 cell 
migration compared to conditioned medium collected from untreated shPKD3-1 C7 cells and 
control shScr cells (Figure 35). 
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Figure 35. Conditioned media collected from tetracycline-treated shPKD3-1 C7 cells displays a reduced 
capacity to promote PC3 cell migration. PC3 cells stably expressing scrambled or PKD3-targeting shRNA (clones 
shScr and shPKD3-1 C7) were pretreated with or without 1 µg/mL tet for 5 days, then replated at equal densities in 
serum-free media. Conditioned media was collected after 48 h and applied to confluent, normal PC3 cells which had 
just been “wounded” using a 10 µL pipette tip, and the wound was imaged. Twenty-four hours later, images of the 
wound were captured again, and the percent wound healing was calculated by measuring the wound area at 3 
locations along the wound for the initial wound and again at the 24-h time point. The graph shows the mean ± 
S.E.M. of the 3 independent experiments. **, p < 0.01.  
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MMPs are secreted endopeptidases that play critical roles in cell motility, angiogenesis, 
and invasion, and MMP-2 and MMP-9 in particular have been shown to be significant 
modulators of cancer progression (Lokeshwar 1999). While PKD1 has recently been implicated 
in the regulation of MMP-2 and MMP-9 in PC3 and DU145 prostate cancer cells (Biswas et al. 
2010), the role of PKD3 in modulating MMPs has not been investigated. Therefore, we 
performed gelatin zymography to determine whether knockdown of PKD3 reduced the 
gelatinase activities of MMP-2 and MMP-9 detected in conditioned medium. Transient 
transfection typically resulted in 50-80% knockdown for all siRNAs excluding siPKD3-2, which 
was not effective at inhibiting PKD3 expression (Figure 36). Conditioned medium from PC3 
cells transfected with siRNA targeting PKD3 was collected and then run on a polyacrylamide gel 
co-polymerized with 0.1% gelatin. Zymography revealed a reduction in MMP-9 levels in the 
conditioned medium from the PKD3 knockdown cells when using 4 different siRNAs (Figure 
37). MMP-2 was expressed at low levels in these cells and its expression was not altered. This 
effect was also observed when PC3 cells were treated with 50 µM CID755673 or 25 µM kb-
NB142-70, supporting the use of these compounds to study PKD function in prostate cancer cells 
(data not shown). 
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Figure 36. Knockdown of PKD3 using multiple siRNAs targeting PKD3. PC3 cells were transiently transfected 
with non-targeting siRNA (siNT) or one of 5 different siRNAs targeting PKD3. Cells were collected 48 h after 
transfection, and PKD3 levels were assessed by Western blot. With the exception of siPKD3-2, which did not inhibit 
PKD3 expression, all siRNAs (siPKD3-1, siPKD3-5, siPKD3-6, and siPKD3-10) typically resulted in 50-80% 
knockdown of endogenous PKD3. Tubulin was blotted as a loading control. 
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Figure 37. Zymography reveals reduced MMP-9 secreted from PKD3 knockdown cells. PC3 cells were 
transfected with siRNAs targeting different regions of PKD3 or a non-targeting siRNA. Forty-eight hours later, cells 
were replated at equal densities in 6-well plates into serum-free media. Conditioned media was collected after 48 h, 
and zymography analysis was conducted as described in the “Materials and Methods.” The band represents MMP-9, 
as determined by molecular weight comparison with a purified, recombinant MMP-9 control. 
 
To determine whether this reduction of MMP-9 activity was due to alteration in MMP-9 
gene transcription rather than impairment of MMP-9 secretion, we performed RT-qPCR analysis 
and determined relative amounts of MMP-9 transcripts in multiple tet-induced PKD3 
knockdown clones. Interestingly, we found that PKD3 knockdown caused no change in MMP-9 
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transcript levels for either clone shPKD3-1 C2-1 or clone shPKD3-1 C2-3 (Figure 38A). 
Similarly, tet-treatment did not affect transcript levels of MMP-9 in control shScr cells. Since 
PKD has also been implicated in the regulation of MMP-14 through modulation of class IIa 
HDAC nuclear localization (Ha et al. 2008a; Wang et al. 2008), we investigated whether MMP-
14 levels were also altered in our PKD3 knockdown cells. We again found no changes in levels 
of MMP-14 transcripts when shPKD3-1 C2-1 or shPKD3 C2-3 cells were treated with tet for 5 
days (Figure 38B). These results suggest that PKD3 is not involved in the regulation of 
transcription of these factors, but rather is altering their secretion. 
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Figure 38. Inducible knockdown of PKD3 does not alter MMP-9 or MMP-14 mRNA. The stable clones shScr, 
shPKD3-1 C2-1, or shPKD3-1 C2-3 were pretreated with or without 1 µg/mL tet for 5 days. Cells were collected 
and total RNA was isolated. RT-qPCR analysis was performed as described in the “Materials and Methods” to 
determine MMP-9 (A) or MMP-14 (B) transcript levels relative to GAPDH. 
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4.2.4  PKD3 knockdown reduces secretion of several key cytokines 
 
To examine if there might be a global effect on other secretory pathways, such as inflammatory 
pathways that have been implicated in prostate cancer progression (MacManus et al. 2007; 
Reiland et al. 1999; Seaton et al. 2008), we performed a cytokine antibody array using 
conditioned medium collected from our tet-induced shPKD3-1 C7 cells. The array revealed that 
tet-induced knockdown of PKD3 caused a significant reduction in the majority of the cytokines 
on the array (Figure 39A-B, Appendix B for antibody array map). For example, IL-3 and IL-6 
were reduced to ~70% of the untreated control, TGFβ and TNFα were decreased to almost 
undetectable levels, and the chemoattractant proteins monocyte chemotactic protein (MCP) 1, -2, 
and -3 were reduced to only 20-40% of the untreated control. Tet-treatment itself had no effect 
on the secretion of cytokines in the shScr cells. 
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Figure 39. Knockdown of PKD3 modulates secretion of various cytokines in a membrane-based array. The 
stable clones shScr and shPKD3-1 C7 were pretreated with or without 1 µg/mL tet for 5 days and then replated at 
equal densities into serum-free media. Conditioned media was collected after 2 days and subjected to the cytokine 
antibody array following the manufacturer’s directions. Chemiluminescent detection of protein spots for each of the 
4 samples is shown (A). Boxes indicate spots corresponding to the following cytokines: Box 1, IL-1α, IL-2; Box 2, 
IL-13, IL-15; Box 3, MCP-3, MIG, RANTES; Box 4, GM-CSF, GRO, GROα; Box 5, IL-3, IL-5, Il-6; Box 6, INF-γ, 
MCP-1, MCP-2; Box 7, TGF-β1, TNF-α, TNF-β; Box 8, IL-7, Il-8, IL-10. B, Densitometry analysis arising from 
several exposures of the chemiluminescent blots. Statistical analysis was performed using the student’s t-test. *, p < 
0.05; **, p < 0.01; ***, p < 0.001.  
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To confirm these array results, we analyzed the levels of several key cytokines secreted 
into the media by ELISA. Our data showed that tet-induced PKD3 knockdown caused a 
significant reduction in the levels of IL-6, IL-8, and GROα/CXCL-1 secreted from shPKD3-1 
C2-3 cells (Figure 40A). Specifically, we found that tet-induced PKD3 knockdown in shPKD3-1 
C2-3 cells reduced IL-8 secretion to less than 40% of the levels detected in conditioned medium 
from the untreated shPKD3-1 C2-3 cells and IL-6 secretion was reduced to only 75% of the 
control. To further validate our results, we measured cytokine secretion in prostate cancer cells 
depleted of endogenous PKD3 by multiple siRNAs. Figure 40B shows that transient knockdown 
of PKD3 using several siRNAs targeting different regions of PKD3 also caused a potent 
reduction in IL-6, IL-8, and GROα/CXCL-1 secretion in both PC3 and DU145 cells. To examine 
whether PKD kinase activity is required for this process, we investigated the effects of our 
previously-described novel PKD inhibitors CID755673 and kb-NB142-70 on cytokine secretion 
in PC3 cells (LaValle et al. 2010a; Sharlow et al. 2008). We found that treatment with either 
inhibitor caused a marked reduction in the secretion of IL-6, IL-8, and GROα/CXCL-1 (Figure 
41). In fact, 25 µM kb-NB142-70 reduced secretion of each of these cytokines to only 
approximately 10% of the DMSO-treated control.  
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Figure 40. Knockdown of PKD3 reduces secretion of IL-6, IL-8, and GROα/CXCL-1. A, The stable clones 
shScr or shPKD3-1 C2-3 were pretreated with or without 1 µg/mL tet for 5 days and then replated at equal densities 
into serum-free media. Conditioned media was collected after 2 days and subjected to ELISA analysis to determine 
levels of IL-6, IL-8, or GROα/CXCL-1 secreted into the media. B, PC3 and DU145 cells were transfected with 
siRNAs targeting different regions of PKD3 or non-targeting siRNA. Two days after transfection, cells were 
replated at equal densities into serum-free media. Conditioned media was collected after 2 days and subjected to 
ELISA. For IL-8 ELISAs, conditioned media was diluted up to 20-fold in Assay Diluent B, provided in the ELISA 
kit. The data represent the mean ± S.E.M. from duplicate samples of 2-3 independent experiments (n = 4-6 for each 
sample). *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
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Figure 41. Antagonizing PKD activity reduces secretion of IL-6, IL-8, and GROα/CXCL-1. PC3 cells were 
treated with the indicated inhibitors for 48 h in serum-free media. The conditioned media was then collected, and 
ELISA was performed as before. For IL-8 ELISAs, conditioned media was diluted up to 20-fold in Assay Diluent B, 
provided in the ELISA kit. The data represent the mean ± S.E.M. from duplicate samples of 2-3 independent 
experiments (n = 4-6 for each sample). *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
 
 
To determine whether the effects of PKD3 knockdown on levels of secreted IL-6, IL-8, 
and GROα/CXCL-1 were due to transcriptional regulation rather than regulation of secretion, 
RT-qPCR was performed on total RNA extracted from shPKD3-1 C2-1 and shPKD3-1 C2-3 
cells treated with or without tet. As shown in Figure 42, after 5-day tet treatment to induce 
PKD3 knockdown, no changes were detected in IL-6, IL-8, or GROα/CXCL-1 transcript levels 
compared to untreated control cells. Similarly, no changes in transcript levels were observed in 
the control shScr cells with or without tet treatment. These data suggest that knockdown of 
endogenous PKD3 or inhibition of PKD by chemical inhibitors blocks secretion, but not 
transcription, of key cancer-promoting factors in prostate cancer cells, likely due to global 
impairment of the secretory pathway. 
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Figure 42. Tetracycline-induced knockdown of PKD3 does not modulate IL-6, IL-8, or GROα/CXCL-1 
transcript levels. The stable clones shScr, shPDK3-1 C2-1, and shPKD3-1 C2-3 were pretreated with or without 1 
µg/mL tet for 5 days. Cells were collected, and total RNA was isolated. RT-qPCR analysis was performed, and IL-6, 
IL-8, and GROα/CXCL-1 transcript levels relative to GAPDH control were determined.  
 
 
4.3  DISCUSSION 
 
Increasing evidence supports a major role for PKD in cancer progression. Here, we have 
established an essential role for PKD3, the least-studied member of the PKD family, in the 
progression of prostate cancer. We have demonstrated, in multiple prostate cancer cell lines, that 
specific knockdown of PKD3 expression using RNAi technology reduces proliferation, motility, 
and secretion of key cancer-promoting factors, including IL-6, IL-8, and GROα/CXCL-1. 
Furthermore, effects of our novel PKD inhibitors CID755673 and kb-NB142-70 have mimicked 
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those of targeted PKD knockdown. These data indicate that PKD3 is a viable target for the 
development of novel chemotherapeutics in prostate cancer treatment, and that our new class of 
PKD inhibitors can be used, albeit with caution, to study PKD function in cells. 
In a previous report, we showed that PKD3 is upregulated in human prostate tumors and 
demonstrated increased nuclear accumulation in advanced-stage prostate cancer (Chen et al. 
2008). Furthermore, transient knockdown of PKD3 by 2 different siRNAs caused a significant 
reduction in PC3 cell proliferation, an effect that was likely mediated by signaling through Akt 
and ERK (Chen et al. 2008). This is in contrast to reports by Balaji and colleagues, who have 
demonstrated an almost tumor-suppressor-like function for PKD1 in prostate cancer (Mak et al. 
2008), highlighting potential isoform-specific functions of PKD and necessitating further study 
into the specific role of the PKD3 isoform in prostate carcinogenesis. Here, we have reported the 
development of a PC3 cell line stably expressing a tetracycline-inducible shRNA targeting 
PKD3. Addition of tet caused downregulation of endogenous PKD3 in 4 clones generated using 
this model (Figure 29). We found that this tet-induced PKD3 knockdown led to reduced cell 
proliferation, in accordance with our previous report using a transient knockdown approach. We 
also demonstrated that knockdown of PKD3 significantly inhibits prostate cancer cell migration 
and invasion, which implies that PKD3 may contribute to tumor metastasis and play a role in the 
progression of a primary prostate tumor into a more aggressive metastatic phenotype.  
It is noteworthy that even with incomplete knockdown (50% - 65%) of PKD3, dramatic 
effects on prostate cancer cell proliferation and motility were observed, implying that PKD3 may 
affect multiple tumor-promoting pathways. In this study, when the conditioned medium from 
PKD3 knockdown cells was applied to normal PC3 cells, it resulted in significant inhibition of 
cell migration. Upon further investigation, we found that knockdown of PKD3 by shRNA caused 
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a global reduction in cytokine secretion in PC3 prostate cancer cells. These results were 
confirmed by ELISA for several significant targets, including IL-6, IL-8, and GROα/CXCL-1. 
Importantly, RT-qPCR analysis revealed no changes in the transcript levels of these proteins, 
suggesting that the reduced detection of cytokines was due to inhibition of secretion rather than 
gene expression. Thus, our data indicate that the robust effects of this partial PKD3 knockdown 
may be due to inhibition of the secretion of key cancer-promoting factors, thereby mediating 
several signaling pathways through reduction of autocrine and paracrine signaling. 
Pro-inflammatory cytokines such as IL-6, IL-8, and GROα/CXCL-1 have well-
documented, significant roles in prostate cancer progression (Mishra et al. 2011; Sciume et al. 
2010). IL-8 in particular has been demonstrated to have various functions in cancer cells that 
promote angiogenesis, migration, metastasis, and proliferation, and is significantly upregulated 
in human prostate tumors (Murphy et al. 2005; Waugh and Wilson 2008). Functionally, IL-8 has 
been shown to regulate Akt expression and activity in androgen-independent prostate cancer 
cells (MacManus et al. 2007), promote the  activity of the cell motility regulators RhoGTPase, 
RacGTPase, and Cdc42GTPase in prostate cancer cells (Waugh and Wilson 2008), and modulate 
expression of the androgen receptor and the androgen-independent state (Araki et al. 2007; 
Seaton et al. 2008), emphasizing the significance of this important cytokine in prostate cancer 
progression. Besides signaling in an autocrine fashion to stimulate cell growth and motility, these 
factors are also regulators of the tumor microenvironment (Coussens and Werb 2002). They have 
been shown to facilitate recruitment of immune system cells to the site of the tumor, which help 
tumors to “escape” immunosurveillance (Rescigno et al. 2007; Wilczynski and Duechler 2010), 
and also are potent stimulators of angiogenesis through communication with endothelial cells 
(Vindrieux et al. 2009). We have demonstrated that there is indeed reduced secretion of multiple 
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of these critical angiogenic cytokines with PKD3 knockdown, and this may account for the very 
potent effects on prostate cancer cell proliferation and motility seen in our cellular studies. 
PKD has been long known to regulate protein trafficking; however, more recent studies 
have also begun to reveal a link between PKD function and the expression/secretion of 
cytokines. For example, a recent report showed that VEGF treatment of endothelial cells 
stimulated PKD1-dependent secretion of multiple cytokines, possibly mediating angiogenesis 
and the inflammatory response (Hao et al. 2009). In this study, researchers found that silencing 
of PKD1 or PKD2 through use of siRNA or treatment with the non-specific inhibitor Gö6976 
caused reduced VEGF-stimulated expression and secretion of IL-6, IL-8, and GROα. However, 
they found no effects of PKD3 knockdown on cytokine secretion. In the present study, we 
demonstrate a very potent effect of PKD3 knockdown (using shRNA or siRNA) or pan-PKD 
inhibition (using PKD inhibitors) on secretion of these cytokines. This discrepancy can be 
explained by the relatively low expression of PKD3 in endothelial cells, which is in contrast to 
the high expression and likely aberrant hyperactivity of PKD3 in our PC3 and DU145 cells. It is 
plausible that the high expression of PKD3 in our multiple prostate cancer cell lines contributes 
to a constitutive hyperactivity of the secretory pathway, leading to increased secretion of key 
tumor-promoting factors and enhancing autocrine growth/motility signals. Furthermore, while 
specific PKD3 knockdown by shRNA and siRNA had robust effects on the secretion of multiple 
cytokines, pan-PKD inhibition by the PKD inhibitors CID755673 and kb-NB142-70 caused an 
even more dramatic reduction in cytokine secretion (Figure 41). This synergism suggests that 
PKD3 and PKD2, the other PKD isoform expressed in PC3 cells, likely have redundant effects in 
mediating cytokine secretion in prostate cancer cells, and this should be confirmed using specific 
PKD2 siRNAs in future studies. Thus, though it is clear that PKD has a role in the modulation of 
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cytokines, it is also clear that these events could be context- and isoform-dependent. Further 
investigations into the mechanisms through which PKD3 mediates secretion of these cytokines 
and potential isoform-specific effects are clearly warranted.    
In conclusion, we present convincing evidence of the tumor-promoting functions of 
PKD3 in prostate cancer progression. We have shown that the cumulative effects of reduced 
cytokine secretion can cause significant changes in cancer cell proliferation and motility, and we 
have demonstrated that a reduction in PKD3 expression can have profound effects on cancer-
related phenotype.  
  
128
 
 
5.0  VALIDATION OF PROTEIN KINASE D3 AS A NOVEL THERAPEUTIC 
TARGET IN PROSTATE CANCER TREATMENT THROUGH USE OF TUMOR 
XENOGRAFT MODELS 
 
 
5.1  INTRODUCTION 
 
While the use of cell lines and in vitro studies are certainly useful, tumor xenograft models are 
much more effective means for understanding the biology and pathology of prostate cancer 
progression in a relavant tumor microenvironment (Chung et al. 2007). In the study of prostate 
cancer, a multitude of xenograft models, including subcutaneous xenografts, orthtopically 
implanted xenografts, cardiac injection models, and bone xenografts, have greatly increased our 
understanding of the mechanisms of progression to androgen dependence (Corey et al. 2003; 
Harper et al. 2004; Legrier et al. 2004; Zhou et al. 2004), functions of the tumor 
microenvironment (Kumano et al. 2008; Shaw et al. 2010; Yang et al. 2005), primary sites of 
metastasis and the ability of prostate cancer cells to form metastases (Angelucci et al. 2004; 
Chung et al. 2007; Margheri et al. 2005; Thudi et al. 2011), and the preclinical efficacy of 
potential novel chemotherapeutics (Dahmani et al. 2010; Hasegawa et al. 2011; Hwang et al. 
2010; Kim et al. 2011). Furthermore, the use of xenograft models allows researchers to 
investigate the involvement of specific proteins in the progression of prostate cancer in vivo. 
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In Chapter 4, we discussed reports demonstrating aberrant and differential expression of 
PKD1 and PKD3 in human prostate cancer tissues and cell lines (Chen et al. 2008; Jaggi et al. 
2003). The additional studies presented in this dissertation in Chapters 3 and 4 suggest that the 
PKD isoenzymes, or, more specifically, PKD2 and PKD3, promote tumor cell growth and 
motility in the context of prostate cancer, and that targeting them via specific RNAi or inhibitors 
causes substantial reductions in prostate cancer cell growth and motility. Thus, although the PKD 
isoforms are differentially implicated in prostate cancer, it is undeniable that they play critical 
roles in the regulation of prostate cancer cell proliferation and invasion. 
Despite the variety of studies in prostate cancer cell lines and evidence of aberrant 
expression in human tumor tissues, in vivo animal studies providing evidence of the role of PKD 
in prostate cancer progression have previously not been reported. Here, we describe the use of a 
tetracycline-inducible PKD3 knockdown prostate cancer cell line in both subcutaneous and 
orthotopic xenograft models, providing significant evidence that PKD3 plays a tumor-promoting 
role in prostate cancer progression in vivo. Our results demonstrate that inducible knockdown of 
PKD3 causes substantial reduction in the growth of subcutaneous xenograft tumors in nude mice. 
Furthermore, we show that inhibition of PKD3 expression results in decreased levels of 
intratumoral GROα/CXCL-1, a cytokine involved in multiple cancer-promoting pathways. These 
data validate PKD3 as a promising therapeutic target in prostate cancer treatment, expand our 
understanding of the molecular mechanisms of PKD function in prostate cancer progression, and 
support the further development of potential chemotherapeutic agents targeting this crucial 
family of serine/threonine kinases. 
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5.2  RESULTS 
 
5.2.1  Knockdown of PKD3 halts growth of subcutaneous xenograft tumors in mice 
 
In order to validate that PKD3 is indeed a significant regulator of prostate tumor growth in vivo, 
we studied the ability of PKD3 knockdown to inhibit growth of PC3 tumors inoculated 
subcutaneously in nude mice. We first established tumors in nude male mice using shScr or 
shPKD3-1 C7 cells from our tet-inducible PKD3 knockdown model system. Five days after 
inoculation of the tumor cells, we administered 1 mg/mL doxycycline (dox), a tetracycline 
analog, via drinking water to half the mice bearing shScr tumors and half the mice bearing 
shPKD3-1 C7 tumors (4 groups: shScr No Dox, shScr +Dox, shPKD3-1 C7 No Dox, shPKD3-1 
C7 +Dox; n = 10-11 mice per group). We measured tumor volume 3 times a week for 25 days at 
which time the shScr tumors were nearing 20 mm in diameter, necessitating euthanasia. While 
dox itself had no effect on tumor growth in the shScr mice, we saw a very potent reduction in 
tumor volume in dox-treated mice bearing shPKD3-1 C7 tumors (Figure 43A, C). After the 25-
day experiment, tumor volume for the shPKD3-1 C7 +dox group measured only 100 mm3 on 
average, compared to an average of 325 mm3 for the no dox shPKD3-1 C7 group, a reduction of 
nearly 70%.  Mice experienced no changes in weight due to tumor growth or dox treatment 
during the course of the study (Figure 43B).  
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Figure 43. Doxycycline-induced knockdown of PKD3 in PC3 cells slows growth of subcutaneous tumor 
xenografts in mice. Male nude mice were injected subcutaneously in the right flank with either shScr or shPKD3-1 
C7 cells (4.0 x 106 cells resuspended 1:1 in BD Matrigel). Five days following injection, mice were randomized and 
half the mice from each group were given dox at 1 mg/mL via drinking water. Tumor volume (A) and mouse weight 
(B) were measured every 2-3 days. The experiment was performed using 5-6 mice per group and was independently 
repeated twice for a total of 10-11 mice per group. Statistical significance was determined using the Mann-Whitney-
Wilcoxon test. C, Representative images of the excised tumors. **, p < 0.01; ***, p < 0.001. 
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5.2.2  Inducible knockdown of PKD3 results in reduced levels of intratumoral 
GROα/CXCL-1 
 
To investigate the potential mechanisms leading to reduced tumor growth in our model, we 
performed ELISA analysis of lysates prepared from the excised tumors. The ELISAs revealed a 
significant reduction in intratumoral GROα/CXCL-1, but not IL-8 (Figure 44). In fact, in 
shPKD3-1 C7 +Dox tumors, levels of GROα/CXCL-1 were reduced to approximately 55% of 
the no dox control. This significant difference indicates that PKD3 modulates levels of this 
cytokine in vivo, and this may contribute to the reduced tumor growth we saw in shPKD3-1 C7-
derived tumors.  
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Figure 44. PKD3 knockdown causes reduction in intratumoral GROα/CXCL-1, but not IL-8. Excised tumors 
were cut into small pieces and lysed as described in the “Materials and Methods.” Protein concentration was 
determined by BCA Protein Concentration Assay Kit, and equal amounts of protein were subjected to ELISA for 
detection of GROα/CXCL-1 (A) or IL-8 (B) following the manufacturer’s instructions. For each tumor sample, 
duplicate measurements were determined, and tumors from 4-5 mice in each group were analyzed. *, p < 0.05. 
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5.2.3  Inducible knockdown of PKD3 reduces growth of orthotopic prostate xenograft 
tumors 
 
While the above subcutaneous xenograft mouse model gives us vital information about the 
ability of prostate cancer cells to form tumors and vascularize, it is well recognized that there are 
many limitations to using this model (Chung et al. 2007; Kerbel 2003). For example, tumor bits 
or cells implanted subcutaneously rarely metastasize, are not exposed to the site-specific 
microenvironment, and are not always accurate predictors of subsequent clinical investigations 
(Sano and Myers 2009). Therefore, many researchers have begun using orthotopic implantation 
models to study the pathogenesis of specific cancers in mouse models, including prostate cancer 
(Chung et al. 2007; Park et al. 2010).   
  Here, we have developed an orthotopic xenograft model using our inducible PKD3-
knockdown cell lines. In this small-scale study using 3-4 mice for each group, we investigated 
whether dox-induced PKD3 knockdown could reduce growth of orthotopic prostate tumors. For 
each cell line, we injected 0.5 x 106 cells into the dorsolateral lobe of the prostate in 8-week old 
male nude mice. Fourteen days following injection, we began treatment using 1 mg/mL dox in 
the animals’ drinking water. We continuously monitored mice for signs of pain, discomfort, 
difficulties urinating, and weight loss. In general, we noticed that mice inoculated with shScr 
cells began to lose weight around day 20 and more rapid weight loss was observed after day 25 
(Figure 45C). Mice were euthanized at day 31, and full necropsies were performed. Also, 
primary tumors were excised and weighed. We found that the average weight of the tumors 
arising from shPKD3-1 C7 cells was less, though statistical significance was not indicated due to 
the small sample size (Figure 45A-B). Necropsies revealed that the shScr +Dox mice, in 
  
134
addition to having larger primary tumors, generally had small tumors growing all over the 
abdomen, with some found on the liver and in the mesentery. At the time, we were unable to 
quantify the number of these tumors. Notably, none of the shPKD3-1 C7 +Dox mice had these 
peritoneal tumors, but only had generally small tumors localized in the prostate. All mice in the 
study developed at least primary prostate tumors, giving us a 100% tumor take rate. This high 
take rate was unexpected since this was an early pilot study; however, very high tumor take rates 
have been reported for several orthotopic prostate xenograft models in the literature, particularly 
if the tumor cells are injected with Matrigel (Ruggeri et al. 2003; Saar et al. 2010). These 
promising data indicate that a more in-depth, full-scale study using this inducible PKD3 
knockdown model is warranted.  
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Figure 45. PKD3 knockdown causes reduced growth of orthotopic prostate tumors in mice. For orthotopic 
prostate xenograft, 0.5 x 106 shScr (n = 4) or shPKD3-1 C7 (n = 3) cells were resuspended 1:1 in BD Matrigel (total 
volume 10 µL) and injected directly into the dorsolateral lobe of the prostates of 8-week old male nude mice. 
Fourteen days following the injection, mice were given drinking water containing 1 mg/mL dox. Dox-containing 
water was refreshed every 2 days, and mice were monitored as described in the “Materials and Methods” for weight 
loss, pain, and discomfort. Thirty-one days following orthotopic injection, mice were sacrificed, and tumors were 
excised and weighed. Total necropsies were performed to determine the presence of metastases. Weight of the 
excised tumor was plotted (A), and representative images of shScr and shPKD3-1 C7 primary prostate tumors are 
shown (B). Mouse weight was monitored over the course of the experiment (C). ns, not significant; *, p < 0.05; **, 
p < 0.01. 
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5.3  DISCUSSION 
 
Recent studies of PKD function in prostate cancer cells have revealed multiple roles in cell 
proliferation and motility pathways, often with conflicting evidence for PKD1 and PKD3 
reported in the literature (Biswas et al. 2010; Chen et al. 2008; Jaggi et al. 2005) Furthermore, 
the studies presented in Chapters 3 and 4 of this dissertation clearly support a tumor-promoting 
role for PKD2 and PKD3 in prostate cancer. However, though we can gain much mechanistic 
insight from cellular models, it is in vivo models of cancer progression that bestow us with the 
most useful and clinically-relevant information. Therefore, we sought to establish whether PKD3 
could modulate the growth of prostate tumors in vivo, as an extension to the cellular work we 
completed in Chapter 4. In this study, we provide evidence that inhibition of PKD3 expression 
using a tetracycline-inducible PKD3 knockdown model reduces the growth of both subcutaneous 
and orthotopic prostate xenografts. We found significant changes in the level of GROα/CXCL-1 
in excised tumors, suggesting that PKD3 may regulate tumor growth through modulation of 
cytokine levels. The results presented here validate PKD3 as a promising therapeutic target in the 
treatment of prostate cancer and support the further development of PKD-targeted therapies. 
 The chemokine GROα/CXCL-1 has been studied in a variety of cancers, and has been 
found to promote proliferation, invasion, and angiogenesis in many different contexts 
(Haghnegahdar et al. 2000; Ogata et al. 2010; Reiland et al. 1999; Wen et al. 2006). In prostate 
cancer, GROα/CXCL-1 was shown to promote invasion and chemotaxis in PC3 cells (Reiland et 
al. 1999). Thus, the significant PKD3-dependent reduction in intratumoral GROα/CXCL-1 is an 
important observation that may explain in part the reduced tumor growth we observed in the 
shPKD3-1 C7-derived tumors. Though we do not yet know the mechanisms through which 
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PKD3 is mediating GROα/CXCL-1 expression in vivo, our cellular studies suggest that 
downregulation of PKD3 impairs the secretory pathway rather than transcription of this 
important tumor-promoting factor.  
The subcutaneous xenograft model is the most commonly used tumor xenograft model, 
largely because of the relative ease of implementation when compared to orthotopic models 
(Chung et al. 2007). However, it is becoming increasingly clear that subcutaneous xenograft 
models are inferior to orthotopic models in predicting the success of future clinical trials (Kerbel 
2003; Park et al. 2010; Sano and Myers 2009). Since implantation of tumor cells or xenografts 
orthotopically creates a much more physiologically-relevant tumor microenvironment, the 
orthotopic model is thought to more closely mimic actual tumor development (Chung et al. 
2007). Furthermore, orthotopic tumors often give rise to metastases, whereas the occurrence of 
secondary tumors is very rare in subcutaneous models (Chung et al. 2007). Therefore, with the 
intention of studying PKD3 function in the progression of metastatic prostate cancer, we initiated 
a pilot study using an orthotopic prostate xenograft model. We found slightly reduced growth of 
the primary tumor in the shPKD3-1 C7 +Dox group, compared to the shScr +Dox group. 
Additionally, we observed dramatic weight loss and growth of a substantial number of secondary 
tumors in the abdomen and mesentery in mice inoculated with shScr cells, but not in mice from 
the shPKD3-1 C7 group. The weight loss observed in the shScr group was not due to the dox 
treatment itself, since the mice in the shPKD3-1 C7 group as well as the mice in our 
subcutaneous studies also received this same treatment and did not experience weight loss 
(Figure 43B and Figure 45C). From the necropsies performed on these mice bearing shScr 
tumors, we observed a number of secondary tumors in the abdomen and mesentery, with 1 
mouse showing lesions on the liver, and much larger primary tumors localized at the prostate. 
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These differences, though not statistically significant due to the small sample size, suggest that 
PKD3 may indeed promote the aggressiveness of prostate cancer in vivo, and it is clear that a 
larger study is warranted.  
The results of the xenograft models described in this chapter also demonstrate the 
potential usefulness of this inducible knockdown model system in studying the role of PKD 
function in vivo. A larger scale orthotopic study is underway to investigate whether PKD3 
knockdown inhibits the metastasis of prostate tumors. Future studies using this model can also be 
used to investigate PKD3-mediated mechanisms of in vivo tumor growth and metastasis 
including regulation of angiogenesis by Matrigel plug assay (Akhtar et al. 2002). Additionally, 
this model can be used to determine whether PKD knockdown sensitizes tumors to established 
chemotherapeutic agents such as docetaxel. 
In conclusion, we have presented evidence that PKD3 is a valid and promising 
therapeutic target in prostate cancer, and that targeting PKD3 in vivo results in substantially 
reduced prostate tumor growth. Future in vivo studies using the orthotopic model are required to 
determine the role of PKD3 in prostate cancer metastasis. 
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6.0  CONCLUSIONS 
 
 
In 1955, the National Cancer Institute made an observation that agents tested and validated in 
tumor xenograft models prior to being introduced in the clinic vastly out-performed those that 
were prescreened only in cellular models (Gellhorn and Hirschberg 1955). From this correlation, 
a paradigm shift occurred, and the NCI commenced a large-scale study to screen anticancer 
drugs against a panel of xenograft tumors in mice (Goldin et al. 1961a; Goldin et al. 1961b; 
Goldin et al. 1961c; Oettel and Wilhelm 1955; Stock et al. 1960). The past few decades have 
seen another shift in thought, moving toward anticancer drug development platforms that attempt 
to develop cytotoxic agents through targeting a specific protein or class of proteins (Suggitt and 
Bibby 2005). The protein kinase D family has become one of these promising targets in many 
cancer types, and our understanding of cancer-related PKD functions is rapidly evolving 
(LaValle et al. 2010b). 
In collaboration with our colleagues, Drs. John S. Lazo, Elizabeth R. Sharlow, and Peter 
Wipf, at the University of Pittsburgh, we have developed and characterized a novel class of PKD 
inhibitors. This class of compounds shows high selectivity toward the PKD isoforms and has 
anticancer activities in cellular models of both prostate and pancreatic cancer. Through SAR 
analysis, the parental compound CID755673 evolved into the new lead compound kb-NB142-70, 
which showed greatly increased potency in vitro and in cells. This class of compounds has been 
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used to study PKD function in cells by multiple groups now, and is proving to be a useful 
pharmacological tool (Pilankatta et al. 2011). 
Further studies of PKD function in prostate cancer cells revealed that PKD2 and PKD3 
modulate cell growth and motility. We made a significant observation that conditioned media 
collected from PKD3 knockdown cells slowed cell migration when applied to normal PC3 cells, 
implicating changes in the profile of secreted proteins. Analysis showed substantial reduction in 
MMP-9 secretion and the secretion of multiple cytokines, including IL-8, IL-6, and 
GROα/CXCL-1. Experimental evidence suggests that this effect is not a transcriptionally-
mediated process, but rather may be accounted for by the known role of PKD in modulating 
protein trafficking and fission of plasma membrane-bound vesicles from the Golgi. Finally, 
subcutaneous and orthotopic xenograft models using a tetracycline-inducible PKD3 knockdown 
PC3 cell line have validated PKD as a promising therapeutic target in prostate cancer treatment. 
In this thesis, we have come full circle, describing a novel class of PKD inhibitors with 
anticancer activity in prostate and cancer cells, discovering novel functions for PKD in the 
regulation of tumor-promoting factors and cytokines, and finally using in vivo analysis to 
validate PKD3 as a strong candidate for anticancer therapy in prostate cancer. Though there is 
still much to be learned about the details of PKD function, our studies have provided substantial 
evidence that targeting PKD in cancer cells may lead to novel and potentially efficacious 
therapeutic alternatives to current treatment regimens in prostate cancer and other cancers. 
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APPENDIX A. COMPOUNDS TESTED DURING SAR ANALYSIS AND STRUCTURAL 
OPTIMIZATION 
 
The following Tables detail the structures and activity of all the compounds synthesized and 
tested during SAR analysis and structural optimization of the PKD inhibitors described in this 
dissertation. All Tables were published in the following manuscript:  
 
George KM, Frantz MC, Bravo-Altamirano K, LaValle CR, Tandon M, Leimgruber S, Sharlow 
ER, Lazo JS, Wang QJ, Wipf P. 2011. Design, synthesis, and biological evaluation of PKD 
inhibitors. Pharmaceutics 3(2):186-228. 
 
Table 1. Chemical structures and PKD1 inhibitory activities of CID797718 and its analogs. 
O
N
R5
O
R2
R1
 
Entry Compound 
Structure  IC50 
R1 R2 R5  IMAP-FP PKD1 (µM) radiometric PKD1 (µM) 
1 CID797718 H OH H  13.7 ± 0.42 (n = 3) 2.34 ± 0.16 (n = 3) 
2 kb-NB77-83 H OAllyl H  not inhibitory n.d. 
3 kb-NB77-78 H OTBS H  not inhibitory n.d. 
4 kb-NB77-91 H OH Cbz  not inhibitory n.d. 
5 kb-NB96-47-1 Cl OH H  not inhibitory n.d. 
Entry Compound 
Structure  IC50 
R1 R2 R5  IMAP-FP PKD1 (µM) radiometric PKD1 (µM) 
1 CID797718 H OH H  13.7? ± 0.42 (n = ?) 2.34 ± 0.16 (n = 3) 
2 kb-NB77-83 H OAllyl H  not inhibitory n.d. 
3 kb-NB77-78 H OTBS H  not inhibitory n.d. 
4 kb-NB77-91 H OH Cbz  not inhibitory n.d. 
5 kb-NB96-47-1 Cl OH H  not inhibitory n.d. 
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Table 2. Chemical structure and PKD1 inhibitory activity of CID755673 and its analogs. 
O
NR2
O
R5
n
 
 
Entry Compound 
Structure  IC50 
R2 R5 N  IMAP-FP PKD1 (µM) radiometric PKD1 (µM) cellular PKD1 (µM) 
1 CID755673 OH H 1  0.64 ± 0.03 (n = 3) 0.18 ± 0.02 (n = 5) 11.8 ± 4.0 (n = 3) 
2 kb-NB123-23A OH H 0  12.6 ± 1.3 (n = 3) 1.41 (n = 1) n.d. 
3 kb-NB123-32 OMe H 0  >100 n.d. n.d. 
4 kb-NB96-53 OH H 2  8.3 ± 0.6 (n = 3) 1.03 (n = 1) n.d. 
5 kb-NB96-59 OMe H 2  >100 n.d. n.d. 
6 kb-NB77-56 OMe H 1  2.40 ± 0.14 (n = 3) 2.39 (n = 1) n.d. 
7 kb-NB77-84 OAllyl H 1  2.6 ± 0.2 (n = 3) 1.23 (n = 1) n.d. 
8 kb-NB123-36 OAc H 1  84.89 ± 3.21 (n = 3) n.d. n.d. 
9 kb-NB77-77 OTBS H 1  not inhibitory n.d. n.d. 
10 kb-NB123-37 OMe Me 0  not inhibitory n.d. n.d. 
11 kb-NB142-25 OH Me 1  n.d. 4.0 ± 1.1 (n = 2) n.d. 
12 kb-NB96-04 OMe Me 1  >100 n.d. n.d. 
13 kb-NB123-45-1 OAc Ac 1  not  inhibitory n.d. n.d. 
14 kb-NB165-15 
O
NHO
N
 
 n.d. not inhibitory n.d. 
Entry Compound 
Structure  IC50 
R2 R5 N  IMAP-FP PKD1 (µM) radiometric PKD1 (µM) cellular PKD1 (µM) 
1 CID755673 OH H 1  0.64 ± 0.03 (n = ?) 0.18 ± 0.02 (n = 5) 11.8 ± 4.0 (n = 3) 
2 kb-NB123-23A OH H 0  12.6 ± 1.3 (n = ?) 1.41 (n = 1) n.d. 
3 kb-NB123-32 OMe H 0  not inhibitory n.d. n.d. 
4 kb-NB96-53 OH H 2  8.3 ± 0.6 (n = ?) 1.03 (n = 1) n.d. 
5 kb-NB96-59 OMe H 2  not inhibitory n.d. n.d. 
6 kb-NB77-56 OMe H 1  2.40 ± 0.14 (n = ?) 2.39 (n = 1) n.d. 
7 kb-NB77-84 OAllyl H 1  2.6 ± 0.2 (n = ?) 1.23 (n = 1) n.d. 
8 kb-NB123-36 OAc H 1  84.89 ± 3.21 (n = ?) n.d. n.d. 
9 kb-NB77-77 OTBS H 1  not inhibitory n.d. n.d. 
10 kb-NB123-37 OMe Me 0  not inhibitory n.d. n.d. 
11 kb-NB142-25 OH Me 1  n.d. 4.0 ± 1.1 (n = 2) n.d. 
12 kb-NB96-04 OMe Me 1  not inhibitory n.d. n.d. 
13 kb-NB123-45-1 OAc Ac 1  not  inhibitory n.d. n.d. 
14 kb-NB165-15 
O
NHO
N
 
 n.d. not inhibitory n.d. 
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Table 3. Chemical structures and PKD1 inhibitory activities of CID755673 analogs. 
 
O
NH
Z
R2
O
R1
R3
 
 
Entry Compound 
Structure  IC50 
Z R1 R2 R3  IMAP-FP PKD1 (µM) radiometric PKD1 (µM) 
1 kb-NB77-88 CH2 Cl OH H  1.4 ± 0.1 (n = 3) 0.89 (n = 1) 
2 kb-NB96-21 CH2 F OH H  1.3? ± 0.05 (n = 3) 0.24 (n = 1) 
3 kb-NB96-50 CH2 Cl OAllyl H  not inhibitory n.d. 
4 kb-NB96-47-5 CH2 H OH Cl  >100 n.d. 
5 kb-NB96-43 CH2 Cl OH Cl  not inhibitory n.d. 
6 kb-NB96-02 CH2 Allyl OH H  2.4 ± 0.3 (n = 3) 1.58 (n = 1) 
7 kb-NB96-30 CH2 Propenyl OH H  1.0 ± 0.1 (n = 3) 0.24 (n = 1) 
8 kb-NB123-63 C=O H OH H  14.9 ± 1.2 (n = 3) 0.85 ± 0.11 (n = 2) 
9 kb-NB123-89 CHOH H OH H  24.09 ± 0.71 (n = 3) 1.23 ± 0.21 (n = 2) 
10 kb-NB142-05 C=NNHPh H OH H  21.70 ± 0.52 (n = 3) 1.13  (n = 1) 
11 kb-NB142-11 C=NNHTs H OH H  38.21 ± 1.17 (n = 3) n.d. 
12 kb-NB142-10 C=NOBn H OH H  not inhibitory n.d. 
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Table 4. Chemical structure and PKD1 inhibitory activity of the β-carboline analogs. 
N
H
NHR2
O
n
 
Entry Compound 
Structure  IC50 
R2 n  IMAP-FP PKD1 (µM) radiometric PKD1 (µM) cellular PKD1 (µM) 
1 kb-NB123-59 OH 0  19.4 ± 1.4 (n = 3) 1.57 ± 0.20 (n = 2) n.d. 
2 kb-NB123-57 OH 1  2.14 ± 0.12 (n = 3) 0.13 ± 0.01 (n = 3) >50 (n = 3) 
3 kb-NB123-52 OBn 0  not inhibitory n.d. n.d. 
4 kb-NB123-53 OBn 1  not inhibitory n.d. n.d. 
5 kb-NB142-08 NH2 0  74.4 ± 2.2 (n = 3) 15.74 ± 0.19 (n=2)  n.d. 
6 kb-NB142-01 NH2 1  47.1 ± 2.5 (n = 3) 9.68 ± 1.01 (n=2) n.d. 
7 kb-NB123-93 NHAc 0  not inhibitory n.d. n.d. 
8 kb-NB123-94 NHAc 1  not inhibitory n.d. n.d. 
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Table 5. Chemical structures and PKD1 inhibitory activities of benzothienothiazepinone 
analogs. 
S
NH
S
R2
O
 
Entry Compound 
Structure  IC50 
R2  IMAP-FP PKD1 (µM) radiometric PKD1 (µM) cellular PKD1 (µM) 
1 kb-NB123-66 OBn  not inhibitory n.d. n.d. 
2 kb-NB142-70 OH  0.71 ± 0.02 (n = 3) 0.028 ± 0.002 (n = 3) 2.22 ± 0.59 (n = 3) 
3 kb-NB165-09 OMe  n.d. 0.08 ± 0.01 (n = 4) 3.13 ± 0.54 (n = 3) 
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Table 6. Chemical structures and PKD1 inhibitory activities of analogs with zone I 
modifications. 
S
NH
S
R2
O
R1
R4
 
Entry Compound 
Structure  IC50 
R1 R2 R4  % PKD1 activity at 1 µM radiometric PKD1 (µM) cellular PKD1 (µM) 
1 mcf292-03 H NH2 H  74.4 ± 1.1 (n = 2) 3.17 (n = 1) n.d. 
2 mcf292-08 H N3 H  n.d. 0.08 ± 0.01 (n = 5) 2.17 ± 0.22 (n = 3) 
3 mcf292-05 H N=C=S H  n.d. 2.77 (n = 1) n.d. 
4 mcf292-09 H NHCOCH2Cl H  n.d. 1.50 (n = 1) n.d. 
5 kb-NB165-31 I OH H  13.6 (n = 1) 0.11 ± 0.02 (n = 3) 8.6 ± 2.0 (n = 3) 
6 kb-NB184-52 Br OH H  12.7 ± 0.2 (n = 2) 0.048 (n = 1) n.d. 
7 kb-NB184-38 H H OBn  98.6 ± 4.1 (n = 2) n.d. n.d. 
8 kb-NB184-40 H H OH  99 ± 11 (n = 2) n.d. n.d. 
9 kb-NB184-44 H H OMe  77.5 ± 3.6 (n = 2) n.d. n.d. 
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Table 7. Chemical structures and PKD1 inhibitory activities of zone II and III modifications. 
Y
NH
Z
R2
O
n
 
Entry Compound 
Structure  IC50 
Y Z R2 n  % PKD1 activity at 1 µM radiometric PKD1 (µM) cellular PKD1 (µM) 
1 kb-NB184-22 S=O S OH 1  66.5 ± 6.1 (n = 2) n.d. n.d. 
2 kb-NB184-25 S=O S OMe 1  50.4 ± 2.3 (n = 2) 1.08 (n = 1) n.d. 
3 kb-NB184-45 S S=O OMe 1  97 ± 16 (n = 2) n.d. n.d. 
4 kb-NB165-89 S S OBn 2  84.3 (n = 1) 21.7 (n = 1) n.d. 
5 kb-NB165-92 S S OH 2  16.7 (n = 1) 0.11 ± 0.01 (n = 3) 2.56 ± 0.66 (n = 2) 
6 kb-NB184-02 S S OMe 2  29.5 (n = 1) 0.19 ± 0.03 (n = 3) 18.6 ± 2.0 (n = 3) 
7 kb-NB184-36 S O OBn 2  83.3 ± 3.8 (n = 2) n.d. n.d. 
8 kb-NB184-57 S O OMe 2  62.0 ± 3.5 (n = 2) n.d. n.d. 
9 kb-NB184-80 
S
HN
O
OH
CO2Me
 
 91.3 ± 1.5 (n = 2) not inhibitory n.d. 
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Table 8. Chemical structures and PKD1 inhibitory activities of zone IV modifications. 
S
N
S
R2
W
R5
 
Entry Compound 
Structure  IC50 
W R2 R5  % PKD1 activity at 1 µM radiometric PKD1 (µM) 
1 kb-NB165-16 O OMe Me   4.57 ± 0.78 (n = 2) 
2 kb-NB165-17 O OH Me   0.45 ± 0.05 (n = 2) 
3 kb-NB165-75 O OH (CH2)2NH2  55.6 (n = 1) 0.757 (n = 1) 
4 kb-NB165-81 -- OBn H  78.3 (n = 1) 39.6 (n = 1) 
5 kb-NB165-83 -- OH H  92.4 (n = 1) 16.4 (n = 1) 
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Table 9. Chemical structures and PKD1 inhibitory activities of analogs with zone I 
modifications to the pyrimidine scaffold. 
N
N
S
NH
S
R2
O
R4
C4
 
Entry Compound 
Structure  IC50  
 R2 R4  radiometric PKD1 (µM) cellular PKD1 (µM) 
1 kmg-NB4-23  OMe H  0.12 ± 0.03 (n = 4) 6.8 ± 1.3 (n = 3) 
2 kmg-NB4-69A  OH H  25.3 (n = 1) n.d. 
3 kmg-NB5-13C  OMe OMe  >30.0  (n = 2) n.d. 
4 kmg-NB5-15A  OMe OH  >30.0  (n = 2) n.d. 
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APPENDIX B: CYTOKINE ANTIBODY ARRAY MAP 
 
 
a b c d e f g h
1 Pos Pos Neg Neg GCSF GM-CSF GRO GRO-alpha
2 Pos Pos Neg Neg GCSF GM-CSF GRO GRO-alpha
3 IL-1 alpha IL-2 IL-3 IL-5 IL-6 IL-7 IL-8 IL-10
4 IL-1 alpha IL-2 IL-3 IL-5 IL-6 IL-7 IL-8 IL-10
5 IL-13 IL-15 IFN-gamma MCP-1 MCP-2 MCP-3 MIG RANTES
6 IL-13 IL-15 IFN-gamma MCP-1 MCP-2 MCP-3 MIG RANTES
7 TGF-beta1 TNF-alpha TNF-beta Blank Blank Blank Blank Pos
8 TGF-beta1 TNF-alpha TNFbeta Blank Blank Blank Blank Pos
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APPENDIX C: LIST OF ABBREVIATIONS 
 
 
 
Akt: also known as protein kinase B (PKB) 
AR: androgen receptor 
ATP: adenosine triphosphate 
BCA: bicinchoninic acid 
Bcl-2: B-cell lymphoma 2 
BCR-ABL: a fusion protein of Bcr (breakpoint cluster region) and Abl 
Bit1: Bcl-2 inhibitor of transcription 1 
BPKDi: 2'-(cyclohexylamino)-6-(piperazin-1-yl)-[2,4'-bipyridine]-4-carboxamide 
BSA: bovine serum albumin 
C1 domain: phorbol ester/diacylglycerol binding domain 
CaMK: calcium-calmodulin-dependent kinase 
CDK: cyclin-dependent kinase 
CXCL: chemokine (C-X-C motif) ligand 
DAG: diacylglycerol 
DMSO: dimethyl sulfoxide 
dox: doxycycline 
ECL: enhanced chemiluminescence 
ECM: extracellular matrix 
EDTA: ethylenediaminetetraacetic acid 
EGFR: epithelial growth factor receptor 
ELISA: enzyme-linked immunosorbent assay 
EMT: epithelial-to-mesenchymal transition 
ERK: extracellular signal-regulated kinase 
FBS: fetal bovine serum 
GM-CSF: granulocyte-macrophage colony stimulating factor 
GPCR: G protein-coupled receptor 
GRK: G protein-coupled receptor kinase 
GRO: growth-regulated oncogene  
GSK-3β: glycogen synthase kinase 3 beta 
HDAC: histone deacetylase 
HRP: horse radish peroxidase 
Hsp: heat-shock protein 
IC50: half maximal inhibitory concentration 
IL: interleukin 
INF-γ: interferon gamma 
JNK: c-Jun N-terminal kinase 
MARK: microtubule-affinity-regulated kinase 
MCP: monocyte chemotactic protein 
MEF2: myocyte enhancer factor 2 
MEK: mitogen-activated protein kinase kinase 
MET: hepatocyte growth factor receptor 
MIG: monokine induced by INF-γ 
MLCK: myosin light-chain kinase 
MMP: matrix metalloproteinase 
MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide methyl thiazolyl tetrazolium 
NCI: National Cancer Institute 
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NKκB: nuclear factor kappa-B 
Par-1: protease-activated receptor-1 
PC3-TR: PC3 prostate cancer cells stably expressing the tetracycline repressor 
PCNA: proliferating cell nuclear antigen 
PDBu: phorbol 12, 13-dibutyrate 
PGF2α: Prostaglandin F2α 
PH: pleckstrin homology domain 
PI3K: phosphoinositide 3-kinase 
PKC: protein kinase C 
PKD: protein kinase D 
PMA: phorbol 12-myristate 13-acetate  
PMSF: phenylmethylsulfonyl fluoride 
PTEN: phosphatase and tensin homolog 
qd: once a day 
Rac-1: Ras-related C3 botulinum toxin substrate 1 
RANTES: regulated upon activation, normal T-cell expressed, and secreted 
RIN1: Ras and Rab interactor 1 
RTK: receptor tyrosine kinase 
RT-qPCR: quantitative real-time reverse-transcription polymerase chain reaction 
SAR: structure-activity relationship 
SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
shRNA: short hairpin RNA 
SIK: salt-inducible kinase  
siRNA: short interfering RNA 
SphK2: sphingosine kinase 2 
SSH1L: slingshot homolog 1-like 
TBS-T: Tris-buffered saline with 0.01% Tween-20 
tet: tetracycline 
TGF: transforming growth factor 
TGN: trans Golgi network 
TNF: tumor necrosis factor 
VEGF: vascular endothelial growth factor 
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